Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality

DOI: 10.1093/ndt/gfg414
Nephrology Dialysis Transplantation, 2003, 18, 1731-40.

#	Paper	IF	Citations
1377	Management of Renal Osteodystrophy in Peritoneal Dialysis Patients. **2004**, 24, 209-216		15
1376	Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. **2004**, 24, 2391-6		65
1375	The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 1337-8	4.3	
1374	Natural history of vascular calcification in dialysis and transplant patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 2387-93	4.3	131
1373	Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. *Nephrology Dialysis Transplantation*, **2004**, 19, 2307-12	4.3	132
1372	When man turns to stone: extraosseous calcification in uremic patients. **2004**, 65, 2447-62		32
1371	Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?. **2004**, 66, 1315-33		121
1370	Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor?. **2004**, S18-24		21
1369	Vascular calcification in ESRD: Another cloud appears in the perfect storm--but highlights a silver lining?. **2004**, 66, 2467-8		13
1368	fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. **2004**, 4, 988-95		103
1367	Breast arterial calcifications associated with diabetes and hypertension. **2004**, 18, 363-6		24
1366	Cardiac calcification in renal patients: what we do and don't know. **2004**, 43, 234-43		62
1365	Screening to prevent coronary events or screening to detect obstruction?. **2004**, 43, 940; author reply 940-1		2
1364	Correspondence. **2004**, 43, 940-941		
1363	Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy. **2004**, 44, e93-7		44
1362	A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 1480-8	4.3	219
1361	Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. **2004**, 38, 405-16		95

1360	Pathophysiology of vascular calcification in chronic kidney disease. **2004**, 95, 560-7		381
1359	Uremic vasculopathy. **2004**, 24, 413-6		13
1358	Arterial calcification in chronic kidney disease. **2004**, 24, 403-7		13
1357	Vascular biology in uremia: insights into novel mechanisms of vascular injury. **2004**, 11, 310-8		23
1356	Secondary hyperparathyroidism: review of the disease and its treatment. **2004**, 26, 1976-93		63
1355	Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. **2004**, 351, 1296-305		8039
1354	Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment. *Nephrology Dialysis Transplantation*, **2004**, 19, 534-6	4.3	4
1353	Imaging and assessment of vascular calcification in chronic kidney disease patients. **2004**, 13, 637-40		2
1352	Fetuin-A and extraosseous calcification in uremia. **2005**, 14, 337-42		48
1351	Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. **2005**, 14, 519-24		21
1350	Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. **2005**, 14, 525-31		185
1349	The clinical epidemiology of cardiovascular disease in chronic kidney disease. **2005**, 14, 550-7		24
1348	Regional calcium distribution and ultrasound images of the vessel wall in human carotid arteries. **2005**, 231, 263-267		4
1347	How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?. **2005**, 18, 226-38		14
1346	The role of vitamin D in vascular calcification in chronic kidney disease. **2005**, 18, 307-14		44
1345	Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. **2005**, 67, 1062-9		133
1344	Modeling the implications of changes in vascular calcification in patients on hemodialysis. **2005**, 67, 1532-8		19
1343	Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. **2005**, 67, 2015-20		58

1342	Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). **2005**, 67, 2295-304		269
1341	Pathogenesis of vascular calcification in chronic kidney disease. **2005**, 68, 429-36		159
1340	Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?. **2005**, 68, 1973-81		118
1339	Calcification and cardiovascular problems in renal failure. **2005**, S120-7		45
1338	Connections between vascular calcification and progression of chronic kidney disease: therapeutic alternatives. **2005**, S142-51		16
1337	Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. **2005**, 8, 549-61		30
1336	Hypertension, antihypertensive agents and outcomes following renal transplantation. **2005**, 19, 181-92		69
1335	Association of conjunctival and corneal calcification with vascular calcification in dialysis patients. **2005**, 45, 550-6		7
1334	Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. **2005**, 45, 494-501		266
1333	Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. **2005**, 46, 455-63		97
1332	"Missing" inhibitors of calcification: general aspects and implications in renal failure. **2005**, 20, 383-8		21
1331	Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. **2005**, 20, 380-2		32
1330	Pathogenesis of vascular calcification in dialysis patients. **2005**, 9, 265-270		55
1329	Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 917-28	12.7	130
1328	Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2005**, 16 Suppl 2, S95-102	12.7	34
1327	Strategies for improving long-term survival in patients with ESRD. *Journal of the American Society of Nephrology: JASN*, **2005**, 16 Suppl 2, S120-7	12.7	49
1326	Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. **2005**, 39, 489-97		34
1325	Sevelamer hydrochloride: a calcium- and metal-free phosphate binder. **2005**, 2, 823-834		2

1324	Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes. **2005**, 2, 425-437		
1323	The prevalence of carotid artery calcification on the panoramic radiographs of patients with renal disease. **2005**, 34, 16-9		29
1322	Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. *Nephrology Dialysis Transplantation*, **2005**, 20, 1653-61	4.3	144
1321	Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. *Nephrology Dialysis Transplantation*, **2005**, 20, 1676-85	4.3	240
1320	Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1788-93	12.7	333
1319	Quantification of calcification in atherosclerotic lesions. **2005**, 25, 1567-76		41
1318	Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. **2005**, 25, 651-4		52
1317	Regulation of vascular calcification: roles of phosphate and osteopontin. **2005**, 96, 717-22		229
1316	Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3357-64	12.7	113
1315	Accumulation of metals and minerals from phosphate binders. **2005**, 23 Suppl 1, 2-11		17
1314	Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. *Nephrology Dialysis Transplantation*, **2005**, 20, 1140-7	4.3	95
1313	Length of interdialytic interval influences serum calcium and phosphorus concentrations. *Nephrology Dialysis Transplantation*, **2005**, 20, 1643-6	4.3	26
1312	Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. **2005**, 182, 121-7		22
1311	Chronic kidney disease: a risk factor for cardiovascular disease. **2005**, 23, 343-62		31
1310	Inflammation and vascular calcification. **2005**, 23, 64-71		90
1309	The value of computed tomography-derived coronary artery calcification score in coronary artery disease detection in asymptomatic hemodialysis patients. **2005**, 27, 683-8		14
1308	Why do dialysis patients develop a heart of stone and bone of china?. **2005**, 23, 203-10		19
1307	Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients. **2005**, 23 Suppl 1, 12-9		14

1306	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. **2005**, 149, 820-5		205
1305	Vascular calcification in patients with renal failure: culprit or innocent bystander?. **2005**, 23, 373-84		9
1304	New therapies for uremic secondary hyperparathyroidism. **2006**, 16, 87-99		15
1303	Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. **2006**, 16, 100-18		29
1302	Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others). **2006**, 32, 413-26, viii		39
1301	Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. **2006**, 16, 253-8		49
1300	Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. **2006**, 13, 183-8		44
1299	Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. **2006**, 47, 1-8		512
1298	Vascular calcification: pathobiological mechanisms and clinical implications. **2006**, 99, 1044-59		720
1297	VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). *Circulation*, **2006**, 113, 1615-21	16.7	124
1296	Place des nouveaux traitements de l'ostéodystrophie rénale : dérivés 1-hydroxylés de la vitamine D « non hypercalcémiants », complexants non calciques, non magnésiens et non aluminiques des phosphates, et calcimimétiques. **2006**, 21, 9-32		
1295	[Calcific uremic arteriolopathy (calciphylaxis): an independent vascular risk factor?]. **2006**, 27, 181-3		0
1294	The role of mineral metabolism and inflammation on dialysis vascular access failure. **2006**, 7, 77-82		10
1293	Uremic vascular calcification. **2006**, 54, 380-4		22
1292	Hypercalcemia in the emergency department. **2006**, 331, 119-23		30
1291	Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. **2006**, 15, 105-10		50
1290	High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. **2006**, 82, 362-7		35
1289	Foreword. *Nephrology*, **2006**, 11, S1-S1	2.2	1

1288	Vascular calcifications in uremia: old concepts and new insights. **2006**, 19, 60-8	35
1287	Lanthanum: a safe phosphate binder. **2006**, 19, 195-9	64
1286	Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. **2006**, 10, 59-64	51
1285	Vitamin D, Cardiovascular System, and Longevity of Hemodialysis Patients. **2006**, 10, S27-S33	1
1284	Review of dialysate calcium concentration in hemodialysis. **2006**, 10, 326-37	49
1283	Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. **2006**, 36 Suppl 2, 51-62	97
1282	Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. **2006**, 69, 33-43	224
1281	New insights into mineral and skeletal regulation by active forms of vitamin D. **2006**, 69, 218-23	50
1280	Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). **2006**, 69, 1945-53	1260
1279	A simple score predicts future cardiovascular events in an inception cohort of dialysis patients. **2006**, 70, 543-8	9
1278	Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. **2006**, 70, 1577-83	99
1277	Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?. **2006**, 70, 1537-8	34
1276	Pleiotropic effects of the non-calcium phosphate binder sevelamer. **2006**, S16-23	26
1275	Introduction: improving outcomes in chronic kidney disease. **2006**, S1-4	1
1274	Novel insights into vascular calcification. **2006**, S5-9	39
1273	A new era in phosphate binder therapy: what are the options?. **2006**, S10-5	28
1272	Osteogenic regulation of vascular calcification. **2006**, 1068, 327-33	67
1271	Coronary artery calcifications in children with end-stage renal disease. **2006**, 21, 1426-33	94

1270	Cardiovascular Disease in End-stage Renal Disease. **2006**, 8, 10-16		1
1269	Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. **2006**, 47, 888-97		27
1268	Vascular calcification in patients with chronic kidney disease. **2006**, 24, 56-62		22
1267	Glomerular filtration rate on admission independently predicts short-term in-hospital mortality after acute myocardial infarction. **2006**, 26, 408-14		13
1266	Cardiac vascular calcification and QT interval in ESRD patients: is there a link?. **2006**, 24, 451-9		20
1265	Is it practical to screen dialysis patients for vascular calcification?. *Nephrology Dialysis Transplantation*, **2006**, 21, 251-4	4.3	13
1264	Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. *Nephrology Dialysis Transplantation*, **2006**, 21, 1663-8	4.3	49
1263	Vascular calcification--a matter of damage limitation?. *Nephrology Dialysis Transplantation*, **2006**, 21, 1166-9	4.3	20
1262	NDT contributes to a collection of 100 seminal papers published by Oxford University Press. *Nephrology Dialysis Transplantation*, **2006**, 21, 2047-8	4.3	
1261	Inflammation and hypertension: the search for a link. *Nephrology Dialysis Transplantation*, **2006**, 21, 850-3	4.3	114
1260	Vascular calcification and cardiovascular function in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2006**, 21, 707-14	4.3	163
1259	Matrix metalloproteinase inhibition attenuates aortic calcification. **2006**, 26, 1510-6		132
1258	The case against calcium-based phosphate binders. **2006**, 1, 697-703		78
1257	Association of disorders in mineral metabolism with progression of chronic kidney disease. **2006**, 1, 825-31		180
1256	Plasma osteoprotegerin is associated with mortality in hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 262-70	12.7	138
1255	Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, S281-5	12.7	11
1254	Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. **2006**, 1, 209-20		12
1253	High-resolution X-ray microtomography is a sensitive method to detect vascular calcification in living rats with chronic renal failure. **2006**, 26, 2110-6		31

1252	Kidney function and mortality among patients with left ventricular systolic dysfunction. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 244-53	12.7	113
1251	Falsely high ankle-brachial index predicts major amputation in critical limb ischemia. **2006**, 11, 69-74		57
1250	Calcification and cardiovascular health: new insights into an old phenomenon. **2006**, 47, 1027-34		100
1249	Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. **2006**, 104, c33-40		19
1248	Aortic stiffness in patients undergoing hemodialysis is positively related to antigen presenting cell-dependent T-lymphocyte reactivity. **2006**, 28, 63-8		1
1247	Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. **2006**, 318, 90-8		70
1246	Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. **2006**, 98, 905-12		347
1245	What serum calcium can tell us and what it can't. *Nephrology Dialysis Transplantation*, **2006**, 21, 29-32	4.3	38
1244	Kidney disease and cardiovascular risk. **2007**, 58, 123-39		54
1243	Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. **2007**, 27, 75-83		45
1242	Endochondral bone formation is involved in media calcification in rats and in men. **2007**, 72, 574-81		78
1241	Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. **2007**, 72, 1527-34		14
1240	Emerging drugs for hyperphosphatemia. **2007**, 12, 355-65		23
1239	The fallacy of the calcium-phosphorus product. **2007**, 72, 792-6		110
1238	The making of a bone in blood vessels: from the soft shell to the hard bone. **2007**, 72, 533-4		13
1237	Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 122-30	12.7	90
1236	Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. **2007**, 2, 1241-8		231
1235	Causes and consequences of increased arterial stiffness in chronic kidney disease patients. *Kidney and Blood Pressure Research*, **2007**, 30, 97-107	3.1	69

1234	Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 2116-24	12.7	203
1233	Association of serum fetuin-A levels with mortality in dialysis patients. **2007**, 72, 202-7		140
1232	The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. **2007**, 2, 766-85		25
1231	Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. **2007**, 175, 1259-65		291
1230	Pulse pressure is an independent predictor of aortic stiffness in patients with mild to moderate chronic kidney disease. *Kidney and Blood Pressure Research*, **2007**, 30, 283-8	3.1	7
1229	Implications of levels of serum mineral metabolism markers, albumin and C-reactive protein for treatment costs of patients on maintenance dialysis. **2007**, 106, c17-23		1
1228	Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?. **2007**, 112, 543-55		90
1227	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. **2007**, 25, 871-6		18
1226	New insights into the risk factors for coronary calcifications. **2007**, 25, 1576-7		
1225	Sodium-dependent phosphate cotransporters and vascular calcification. **2007**, 16, 325-8		45
1224	Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. **2007**, 71, 802-7		122
1223	Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. **2007**, 16, 329-35		92
1222	Calciphylaxis: natural history, risk factor analysis, and outcome. **2007**, 56, 569-79		359
1221	Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. **2007**, 195, e65-75		41
1220	Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. **2007**, 72, 709-15		167
1219	Osteoporosis and chronic kidney disease. **2007**, 20, 423-30		49
1218	[Arterial hypertension, chronic renal insufficiency and dialysis]. **2007**, 3 Suppl 3, S156-61		4
1217	Vascular function in patients with end-stage renal disease and/or coronary artery disease: a cardiac magnetic resonance imaging study. **2007**, 71, 68-73		21

1216	Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease?. **2007**, 25, 179-82		27
1215	Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. **2007**, 72, 1130-7		374
1214	Chronic kidney disease-mineral-bone disorder: a new paradigm. **2007**, 14, 3-12		157
1213	Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. **2007**, 67, 1999-2012		53
1212	Clinical assessment of vascular calcification. **2007**, 14, 37-43		20
1211	The Progression and Impact of Vascular Calcification in Peritoneal Dialysis Patients. **2007**, 27, 340-346		29
1210	Come ridurre il rischio cardiovascolare attraverso il controllo del metabolismo calcio fosforo nell'uremico in dialisi, nel Terzo Millennio?. **2007**, 19, 48-53		
1209	Advantage of a low glycemic index and low phosphate diet on diabetic nephropathy and aging-related diseases. **2007**, 54, 359-65		7
1208	Carotid atherosclerosis and cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. **2007**, 40, 1361-6		18
1207	Arterial calcification and stiffness in chronic kidney disease. **2007**, 34, 683-7		20
1206	Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. *Nephrology*, **2007**, 12, 500-9	2.2	56
1205	Patients with vascular calcifications are at increased risk of cardiovascular events: implications for risk factor management and further research. *Journal of Internal Medicine*, **2007**, 261, 235-7	10.8	4
1204	Mineral metabolism disturbances in patients with chronic kidney disease. **2007**, 37, 607-22		37
1203	Animal models--what they can tell us about vascular calcification in CKD. **2007**, 20, 110-2		8
1202	Inhibitors of calcification in blood and urine. **2007**, 20, 113-21		76
1201	The functional cardiovascular consequences of vascular calcification. **2007**, 20, 122-8		16
1200	Techniques and technologies to assess vascular calcification. **2007**, 20, 129-33		32
1199	Vascular calcification and disordered mineral metabolism in dialysis patients. **2007**, 20, 139-43		41

1198	Arterial calcification in dialysis patients and transplant recipients. **2007**, 20, 144-9	15
1197	Renal osteodystrophy, phosphate homeostasis, and vascular calcification. **2007**, 20, 309-15	77
1196	New developments in the management of hyperphosphatemia in chronic kidney disease. **2007**, 20, 337-41	17
1195	Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. **2007**, 20, 302-8	88
1194	Coronary artery calcification, coronary artery stenosis and hyperphosphatemia in hemodialysis patients. **2007**, 11, 81; author reply 82	2
1193	Prevention of aortic calcification by etidronate in the renal failure rat model. **2007**, 558, 159-66	40
1192	Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. **2007**, 11 Suppl 3, S13-21	27
1191	Vascular calcification and fetuin-A deficiency in chronic kidney disease. **2007**, 17, 124-8	52
1190	Long-term outcomes after coronary artery bypass grafting: preoperative kidney function is prognostic. **2007**, 134, 683-9	20
1189	Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. **2007**, 49, 417-25	210
1188	A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. **2007**, 49, 776-85	42
1187	Bone health and vascular calcification relationships in chronic kidney disease. **2007**, 39, 1209-16	32
1186	To what extent can coronary calcification and arterial stiffness be influenced by the nephrologist?. **2007**, 2, S15-S21	
1185	Bone and mineral disorders in pre-dialysis CKD. **2008**, 40, 427-40	59
1184	Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice?. **2008**, 40, 763-70	18
1183	Kalzium-Phosphat- und Knochenstoffwechsel. **2008**, 3, 507-517	3
1182	Cardiovascular complications of pediatric chronic kidney disease. **2008**, 23, 27-39	96
1181	Circulating calcification inhibitors and vascular properties in children after renal transplantation. **2008**, 23, 985-93	18

1180	Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. **2008**, 10, 39		23
1179	Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. *Journal of Bone and Mineral Research*, **2008**, 23, 1798-805	6.3	120
1178	Bone markers predict cardiovascular events in chronic kidney disease. *Journal of Bone and Mineral Research*, **2008**, 23, 1850-8	6.3	72
1177	Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. **2008**, 12, 137-42		4
1176	Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. **2008**, 12, 16-22		25
1175	Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients. **2008**, 12, 254-63		64
1174	Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. *Journal of Internal Medicine*, **2008**, 264, 351-60	10.8	26
1173	[Cardiovascular risk in women with chronic renal failure: mammographic study of vascular calcifications]. **2008**, 50, 54-60		5
1172	A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. **2008**, 51, 445-54		144
1171	A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. **2008**, 51, 952-65		244
1170	Should we be using calcium-containing phosphate binders in patients on dialysis?. **2008**, 4, 118-9		6
1169	The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. **2008**, 48, 1197-203		218
1168	Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. **2008**, 9, 947-54		9
1167	Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. **2008**, 179, 1631-6		25
1166	Hyperphosphatemia of chronic kidney disease. **2008**, 74, 148-57		261
1165	Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. **2008**, 58, 458-71		137
1164	Cystatin C concentration as a predictor of systolic and diastolic heart failure. **2008**, 14, 19-26		43
1163	Vitamin D receptor activators can protect against vascular calcification. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1509-19	12.7	177

1162	The mechanism of phosphorus as a cardiovascular risk factor in CKD. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1092-105	12.7	184
1161	The pathophysiology of vascular calcification: are osteoclast-like cells the missing link?. **2008**, 34 Suppl 1, S16-20		41
1160	Epidemiology and diagnosis of peripheral arterial disease in patients with chronic kidney disease. **2008**, 15, 378-83		19
1159	Battleground: chronic kidney disorders mineral and bone disease--calcium obsession, vitamin d, and binder confusion. **2008**, 3, 168-73		32
1158	Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. **2008**, 18, 91-8		49
1157	Vitamin D deficiency and associated factors in hemodialysis patients. **2008**, 18, 395-9		35
1156	Phosphate is a uremic toxin. **2008**, 18, 27-32		22
1155	Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. **2008**, 46, 217-62		26
1154	A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 997-1002	4.3	70
1153	Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 405-12	12.7	129
1152	Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. **2008**, 3, 61-8		96
1151	Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. **2008**, 3, 179-83		12
1150	Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients. **2008**, 1, i18-i23		2
1149	Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1827-35	12.7	206
1148	The GLUT-1 XbaI gene polymorphism is associated with vascular calcifications in nondiabetic uremic patients. **2008**, 108, c182-7		7
1147	Different risk factors for vascular calcification in end-stage renal disease between diabetics and nondiabetics: the respective importance of glycemic and phosphate control. *Kidney and Blood Pressure Research*, **2008**, 31, 10-5	3.1	19
1146	Media calcification and intima calcification are distinct entities in chronic kidney disease. **2008**, 3, 1599-605		260
1145	Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. **2008**, 3, 836-43		58

1144	The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. **2008**, 3, 36-45		152
1143	Aortic stiffness and diastolic flow abnormalities in end-stage renal disease assessed by magnetic resonance imaging. **2008**, 109, c1-8		10
1142	Vascular calcification is associated with impaired microcirculatory function in chronic haemodialysis patients. **2008**, 108, c121-6		30
1141	Cardiothoracic ratio, malnutrition, inflammation, and two-year mortality in non-diabetic patients on maintenance hemodialysis. *Kidney and Blood Pressure Research*, **2008**, 31, 143-51	3.1	27
1140	Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2008**, 23, 2611-8	4.3	23
1139	Abdominal aortic calcification in dialysis patients: results of the CORD study. *Nephrology Dialysis Transplantation*, **2008**, 23, 4009-15	4.3	106
1138	Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 239-46	4.3	90
1137	Association of renal function with cardiac calcifications in older adults: the cardiovascular health study. *Nephrology Dialysis Transplantation*, **2009**, 24, 834-40	4.3	46
1136	Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. *Nephrology Dialysis Transplantation*, **2009**, 24, 948-55	4.3	155
1135	Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. *Nephrology Dialysis Transplantation*, **2009**, 24, 1314-9	4.3	54
1134	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. **2008**, 74, 265-75		34
1133	Vascular calcification and uremia: what do we know?. **2008**, 28, 339-46		59
1132	Chapter 7 Mechanisms of Arterial Calcification: Spotlight on The Inhibitors. **2008**, 46, 263-293		36
1131	The prevalence of carotid artery calcification on the panoramic radiographs of end-stage renal disease patients with peritoneal dialysis: do incidental findings provide life-saving information?. **2008**, 36, 47-53		12
1130	Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. **2008**, 105, 1643-51		77
1129	Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?. **2008**, 3, 1583-4		38
1128	Vascular calcification: pathobiology of a multifaceted disease. *Circulation*, **2008**, 117, 2938-48	16.7	698
1127	Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. **2008**, S38-43		12

1126	Mechanisms of vascular calcification in chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 213-6	12.7	360
1125	Review: Vascular calcification in chronic kidney disease: the tip of the chalk-berg. **2008**, 8, 264-271		2
1124	Cinacalcet suppresses calcification of the aorta and heart in uremic rats. **2008**, 74, 1270-7		81
1123	Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder. **2008**, 21, 196-213		2
1122	Diffuse vascular calcification in a dialysis patient. **2008**, 73, 890-4		1
1121	Vascular access calcification predicts mortality in hemodialysis patients. **2008**, 74, 1582-7		65
1120	Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. **2008**, 149, 6092-102		13
1119	Cardiovascular risk in dialysis patients: an X-ray vision on vascular calcifications. **2008**, 74, 1505-7		4
1118	Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2008**, 23, 3256-62	4.3	33
1117	Spatial QRS-T angle in peritoneal dialysis patients: association with carotid artery atherosclerosis, coronary artery calcification and troponin T. *Nephrology Dialysis Transplantation*, **2009**, 24, 1003-8	4.3	15
1116	Expression of gremlin, a bone morphogenetic protein antagonist,is associated with vascular calcification in uraemia. *Nephrology Dialysis Transplantation*, **2009**, 24, 1121-9	4.3	12
1115	Response to lack of mortality benefit with sevelamer**2008**, 73, 1093-1094		
1114	Accelerated arterial stiffening and gene expression profile of the aorta in patients with coronary artery disease. **2008**, 26, 747-57		22
1113	Assessing cardiac risk in the renal patient: do the general rules apply?. **2008**, 29, 507-10		3
1112	Chronic Kidney Disease Mineral Bone Disorder. **2008**, 28, 5-10		0
1111	Renal Osteodystrophy. **2008**, 1479-1510		
1110	Giardiasis: Modern Concepts in Control and Management. **2008**, 66, 23-29		6
1109	Vascular and Other Tissue Calcification in Peritoneal Dialysis Patients. **2009**, 29, 9-14		20

1108	Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. **2009**, 5, 185-97		302
1107	Cardiovascular disease in patients with chronic kidney disease. **2009**, 5, 713-22		58
1106	Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. **2009**, 2, 1-8		2
1105	Myocardial calcinosis in chronic renal failure. **2009**, 3, 16-9		12
1104	La gestione dell'iperparatiroidismo secondario nella malattia renale cronica allo stadio 3 e 4. **2009**, 21, 37-42		
1103	Associations between oxidized LDL to LDL ratio, HDL and vascular calcification in the feet of hemodialysis patients. **2009**, 24 Suppl, S115-20		16
1102	Validity and usefulness of aortic arch calcification in chest X-ray. **2009**, 16, 256-64		50
1101	Evaluation of vascular calcifications in CKD patients. **2009**, 32, 81-6		4
1100	Cardiovascular disease in children with CKD or ESRD. **2009**, 5, 229-35		61
1099	Vascular calcification: the three-hit model. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1162-4	12.7	8
1098	Cardiovascular risk and management in chronic kidney disease. **2009**, 5, 287-96		49
1097	Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. **2009**, 4 Suppl 1, S49-55		137
1096	Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. **2009**, 4, 673-9		22
1095	Coronary calcification in patients with chronic kidney disease and coronary artery disease. **2009**, 4, 1892-900		153
1094	OPG/RANK/RANKL signaling system and its significance in nephrology. **2009**, 47, 199-206		26
1093	Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. **2009**, 4, 790-7		78
1092	Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. **2009**, 4, 119-27		28
1091	Vascular access calcification may be only an intermediate factor for mortality. **2009**, 75, 1117-8		1

1090	Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification?. **2009**, 76, 18-22		69
1089	Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. **2009**, 75, 1297-1307		163
1088	The emerging role of phosphate in vascular calcification. **2009**, 75, 890-7		324
1087	Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. *Nephrology Dialysis Transplantation*, **2009**, 24, 3157-62	4.3	48
1086	Does Vascular Calcification Correlate with Pulse Wave Velocity in Hemodialysis Patients?. **2009**, 1, 11-17		3
1085	Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C. **2009**, 296, F60-6		12
1084	Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. **2009**, 2, 267-72		6
1083	Interobserver variability in the measurement of abdominal aortic calcification using unenhanced CT. **2009**, 82, 69-72		12
1082	A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 3389-97	4.3	51
1081	Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. **2009**, 25, 3021-8		58
1080	Fetuin-A protects against atherosclerotic calcification in CKD. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1264-74	12.7	132
1079	Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. **2009**, 53, 524-31		159
1078	Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. **2009**, 4, 221-33		92
1077	Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. **2009**, 4, 1646-54		63
1076	Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Circulation*, **2009**, 119, 1363-9	16.7	307
1075	Is calcitriol life-protective for patients with chronic kidney disease?. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 2285-90	12.7	12
1074	Prediction, progression, and outcomes of chronic kidney disease in older adults. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1199-209	12.7	148
1073	Pulse pressure and presence of coronary artery calcification. **2009**, 4, 316-22		29

1072	Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. **2009**, 4, 401-9		30
1071	Plaque characterization of non-culprit lesions by virtual histology intravascular ultrasound in diabetic patients: impact of renal function. **2009**, 54, 59-65		18
1070	Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. **2009**, 29, 554-61		50
1069	Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. **2009**, 9, 2571-9		39
1068	Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. **2009**, 103, 46-9		22
1067	Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. **2009**, 13, 571-7		36
1066	Long-term outcome of chronic dialysis in children. **2009**, 24, 463-74		63
1065	Progression of coronary calcification in pediatric chronic kidney disease stage 5. **2009**, 24, 555-63		29
1064	Effects of bone and mineral metabolism on arterial elasticity in chronic renal failure. **2009**, 24, 2413-20		20
1063	Phosphathaushalt und Phosphatbindertherapie. **2009**, 4, 401-410		
1062	Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. **2009**, 13, 453-9		70
1061	Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis. **2009**, 13, 518-25		8
1060	Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?. **2009**, 13 Suppl 1, S20-7		12
1059	Coronary calcification and its association with mortality in haemodialysis patients. *Nephrology*, **2009**, 14, 164-70	2.2	17
1058	Relationship between vascular calcification, arterial stiffness and bone mineral density in a cross-sectional study of prevalent Australian haemodialysis patients. *Nephrology*, **2009**, 14, 105-12	2.2	27
1057	Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. *Nephrology*, **2009**, 14, 408-15	2.2	26
1056	Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach. **2009**, 22, 56-63		1
1055	Dermatologic conditions seen in end-stage renal disease. **2009**, 22, 45-55		29

1054	Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. **2009**, 22, 357-62		15
1053	Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. **2009**, 4, 609-15		132
1052	Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. **2009**, 45 Suppl 1, S30-4		13
1051	Insuffisance r□ale chronique´: de la maladie osseuse □la maladie osseuse et vasculaire. **2009**, 33, 33-38		
1050	De la physiopathologie des calcifications vasculaires aux nouveaux marqueurs biologiques chez l□insuffisant r□al chronique. **2009**, 33, 53-61		
1049	Vascular calcification and bone disease: the calcification paradox. **2009**, 15, 405-16		201
1048	Impact of preoperative renal dysfunction on in-hospital mortality after solitary valve and combined valve and coronary procedures. **2009**, 87, 731-6		15
1047	Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). **2009**, 54, 1176-84		63
1046	Vascular calcification: the killer of patients with chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1453-64	12.7	365
1045	Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure. **2009**, 75, 915-28		99
1044	What can a keto acid/amino acid-supplemented protein-restricted diet do for the "butterfly effect" in chronic kidney disease patients?. **2009**, 19, S15-8		4
1043	Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity. **2009**, 67, 234-40		12
1042	Advanced oxidation protein products induce vascular calcification by promoting osteoblastic trans-differentiation of smooth muscle cells via oxidative stress and ERK pathway. **2009**, 31, 313-9		28
1041	Uraemic vascular damage and calcification in children on dialysis. **2009**, 3, 137		
1040	Arterial calcification and its physiological consequences: Ideas from animal models. **2009**, 3, 132		1
1039	The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. **2009**, 205, 55-62		83
1038	Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. **2009**, 205, 385-90		281
1037	Clinical relevance of FGF-23 in chronic kidney disease. **2009**, S34-42		71

1036	Should dialysate calcium concentration be standardised or individualised?. **2009**, 35 Suppl 1, 101-6		4
1035	Vascular calcification in chronic kidney disease: a clinical review. **2009**, 35 Suppl 1, 45-50		9
1034	Soft bones and hard arteries-can we reverse the trend in CKD?. **2009**, 35 Suppl 1, 28-33		3
1033	Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. **2009**, 35 Suppl 1, 71-8		11
1032	Vascular calcification: lessons from scientific models. **2009**, 35 Suppl 1, 51-6		10
1031	Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach. **2009**, 35 Suppl 1, 3-6		6
1030	Vitamin D therapy for chronic kidney disease. **2009**, 29, 85-93		10
1029	Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study. **2009**, 19, 220-7		11
1028	Adherence to K/DOQI bone metabolism guidelines. **2009**, 19, 334-42		2
1027	Adynamic bone disease: clinical and therapeutic implications. **2009**, 18, 303-7		33
1026	Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats. **2009**, 55, 99-105		8
1025	Vasculotropic effects of calcimimetics. **2010**, 19, 32-6		2
1024	Improved assessment of aortic calcification in Japanese patients undergoing maintenance hemodialysis. **2010**, 49, 2071-5		10
1023	Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. *Journal of Bone and Mineral Research*, **2010**, 25, 499-504	6.3	61
1022	Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. **2010**, 14, 43-50		21
1021	Fetuin-A as a risk factor for mortality in hemodialysis patients. **2010**, 122 Suppl 2, 63-7		4
1020	Association of increased hair calcium levels and enhanced augmentation index (AIx): a marker of arterial stiffness. **2010**, 138, 90-8		12
1019	Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. **2010**, 42, 187-94		40

1018	Vascular calcification score on plain radiographs of the feet as a predictor of peripheral arterial disease in patients with chronic kidney disease. **2010**, 42, 773-80		21
1017	Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. **2010**, 42, 999-1006		17
1016	Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. **2010**, 30, 741-8		21
1015	Association of calcium-phosphorus product with blood pressure in dialysis. **2010**, 12, 96-103		5
1014	Progression of Coronary Artery Calcification Using a Multidetector CT on Hemodialysis Patients in One Year. **2010**, 39, 27-32		2
1013	Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. **2010**, 11, 14		60
1012	Screening dialysis patients for vascular calcification. **2010**, 23, 271-6		6
1011	Measuring vascular calcification clinical practice. **2010**, 23, 263-6		2
1010	The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. **2010**, 14, 174-81		55
1009	Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. *Nephrology*, **2010**, 15, 184-9	2.2	14
1008	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. *Nephrology*, **2010**, 15, 575-83	2.2	11
1007	Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. **2010**, 5, 189-94		62
1006	Fetuin-mineral complex reflects extraosseous calcification stress in CKD. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1998-2007	12.7	162
1005	Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. **2010**, 30, 1741-50		57
1004	Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. **2010**, 30, 321-6		33
1003	Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. **2010**, 171, 909-16		19
1002	Cardiovascular Disease in Patients with Chronic Kidney Disease. **2010**, 128-144		1
1001	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. **2010**, 86, 560-6		14

1000	Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. **2010**, 32, 214-23		6
999	Cardiovascular risk in the peritoneal dialysis patient. **2010**, 6, 451-60		105
998	The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. **2010**, 5, 568-75		199
997	Paracrine osteogenic signals via bone morphogenetic protein-2 accelerate the atherosclerotic intimal calcification in vivo. **2010**, 30, 1908-15		99
996	Ten-year experience with sevelamer and calcium salts as phosphate binders. **2010**, 5 Suppl 1, S31-40		34
995	Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. **2010**, 5 Suppl 1, S12-22		46
994	Alteraciones del Metabolismo □eo y mineral en enfermedad renal cr□ica pre-di□□sis. **2010**, 21, 530-540		
993	Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. **2010**, S10-21		97
992	Thoracoabdominal calcifications predict cardiovascular disease mortality in type 2 diabetic and nondiabetic subjects: 18-year follow-up study. **2010**, 33, 583-5		6
991	Chronic Kidney Disease-Mineral Bone Disorder. **2010**, 98-114		
990	Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 1916-23	4.3	32
989	The five most cited NDT articles from 1999 to 2004. *Nephrology Dialysis Transplantation*, **2010**, 25, 2818-24	4.3	1
988	RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). **2010**, 299, F674-80		23
987	Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 1923-9	4.3	51
986	Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. *Nephrology Dialysis Transplantation*, **2010**, 25, 574-81	4.3	21
985	Vascular calcification in chronic kidney disease. **2010**, 119, 111-21		77
984	Renal function, cardiovascular disease risk factors' prevalence and 5-year disease incidence; the role of diet, exercise, lipids and inflammation markers: the ATTICA study. **2010**, 103, 413-22		21
983	Vascular calcification is not an independent predictor of mortality in pre-dialysis adult patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 2804-5; author reply 2805	4.3	3

982	Effects of bone remodelling on calcium mass transfer during haemodialysis. *Nephrology Dialysis Transplantation*, **2010**, 25, 1244-51	4.3	30
981	Malnutrition-inflammation complex syndrome: link between end-stage renal disease, atherosclerosis and valvular calcification. **2010**, 33, 541-3		12
980	Chronic kidney disease-mineral bone disorder (CKD-MBD). **2010**, 7, 447-457		5
979	Unusual presentation of Mönckeberg's sclerosis in the thyroid vessels of three female patients. **2010**, 19, e45-7		2
978	Use of multidetector CT in presurgical evaluation of potential kidney transplant recipients. **2010**, 30, 517-31		13
977	Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 4041-8	4.3	35
976	Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 103-12	12.7	235
975	Diagnóstico y tratamiento de las alteraciones oseominerales asociadas a la enfermedad renal crónica. **2010**, 31, 79-85		1
974	Calcium metabolism in health and disease. **2010**, 5 Suppl 1, S23-30		416
973	Coronary artery calcification and mortality in diabetic patients with proteinuria. **2010**, 77, 1107-14		69
972	Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges. **2010**, 10, 1729-42		7
971	Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. **2010**, 47, 156-63		27
970	Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. **2010**, 391, 1087-92		86
969	The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. **2010**, 36 Suppl 1, 61-7		6
968	Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure. **2010**, 36 Suppl 1, 18-26		15
967	Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. **2010**, 55, 579-92		172
966	Awareness of vascular calcification alters mineral metabolism management. **2010**, 23, 267-70		4
965	[Inflammation and vascular calcifications]. **2010**, 6 Suppl 1, S13-8		0

964	Role of aortic calcification, stiffness and wave reflections in cardiovascular risk in dialysis patients: Baseline data from the CORD study. **2010**, 4, 81		9
963	Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. **2010**, 211, 418-23		42
962	Myeloid CD34+CD13+ precursor cells transdifferentiate into chondrocyte-like cells in atherosclerotic intimal calcification. **2010**, 177, 473-80		32
961	Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. **2010**, 109, 663-72		10
960	The vitamin D system: a crosstalk between the heart and kidney. **2010**, 12, 1031-41		57
959	Recent progress in the treatment of vascular calcification. **2010**, 78, 1232-9		48
958	Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V). **2010**, 11, 2739-50		7
957	Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients. **2011**, 33, 329-33		1
956	Noninvasive imaging for assessment of calcification in chronic kidney disease. **2011**, 7, 567-77		45
955	Cell biological and physicochemical aspects of arterial calcification. **2011**, 79, 1166-77		46
954	Vitamin D and vascular calcification in chronic kidney disease. *Kidney and Blood Pressure Research*, **2011**, 34, 261-8	3.1	30
953	Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. **2011**, 18, 120-31		25
952	Phosphate and cardiovascular disease. **2011**, 18, 113-9		46
951	Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. **2011**, 57, 1480-6		71
950	The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. **2011**, 58, 2372-9		44
949	Consenso metabolismo seo y mineral. Sociedad Argentina de Nefrologa. Versi 2010. Capulo IV. Tratamiento de la hiperfosfatemia y mantenimiento del calcio en pacientes con enfermedad renal crica estadio 5 en disis. **2011**, 32, 32-38		
948	Cardiovascular complications in children with chronic kidney disease. **2011**, 7, 642-9		64
947	Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. **2011**, 79, 1071-9		139

946	Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. **2011**, 6, 153-9		165
945	Epicardial adipose tissue and coronary artery calcification in diabetic and nondiabetic end-stage renal disease patients. **2011**, 33, 770-5		21
944	Direct effects of phosphate on vascular cell function. **2011**, 18, 105-12		90
943	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. *Nephrology Dialysis Transplantation*, **2011**, 26, 1327-39	4.3	397
942	Chronic kidney disease: Medial or intimal calcification in CKD-does it matter?. **2011**, 7, 250-1		8
941	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. **2011**, 6, 693-702		
940	[How to manage mineral metabolism disorders in renal failure]. **2011**, 40, 1043-52		2
939	[Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia]. **2011**, 7, 154-61		1
938	[Atypical obstruction during a hemodialysis catheter replacement]. **2011**, 7, 188-90		
937	High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. **2011**, 215, 116-24		17
936	Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. **2011**, 215, 43-51		35
935	A Review of Sevelamer Hydrochloride in End-Stage Renal Disease Patients on Dialysis. **2011**, 3, CMT.S5990		1
934	Is chronic kidney disease associated with a high ankle brachial index in adults at high cardiovascular risk?. **2011**, 18, 224-30		9
933	Extracellular matrix calcification in chronic kidney disease. **2011**, 20, 360-8		8
932	Smooth muscle cells in pathogenesis of vascular medial cartilaginous metaplasia. **2011**, 90, 1-2		1
931	Calcium phosphate deposition with normal phosphate concentration. -Role of pyrophosphate-. **2011**, 75, 2705-10		49
930	Aortic arch calcification and clinical outcome in patients with end-stage renal disease. **2011**, 223, 79-84		14
929	Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. *Nephrology*, **2011**, 16, 290-8	2.2	98

928	Lateral lumbar X-ray assessment of abdominal aortic calcification in Australian haemodialysis patients. *Nephrology*, **2011**, 16, 389-95	2.2	20
927	Use of cardio-ankle vascular index in chronic dialysis patients. **2011**, 41, 45-51		10
926	The calcium-sensing receptor and calcimimetics in blood pressure modulation. **2011**, 164, 884-93		40
925	Attempting to build solid recommendations on a shaky evidence base. **2011**, 24, 22-4		1
924	A daunting task but largely successful in developing meaningful guidelines. **2011**, 24, 24-7		
923	Should activated vitamin D be used in patients with end-stage renal disease and low levels of parathyroid hormone?. **2011**, 24, 428-30		2
922	Management of coronary artery disease in end-stage renal disease. **2011**, 24, 525-32		1
921	Coronary plaque morphology using virtual histology-intravascular ultrasound analysis in hemodialysis patients. **2011**, 15, 44-50		18
920	Evidence for severe atherosclerotic changes in chronic hemodialysis patients: comparative autopsy study against cardiovascular disease patients without chronic kidney disease. **2011**, 15, 51-7		4
919	Involvement of matrix metalloproteinase-2 in the development of medial layer vascular calcification in uremic rats. **2011**, 15 Suppl 1, 18-22		16
918	FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. **2012**, 16, 53-8		20
917	Vascular calcification: Inducers and inhibitors. **2011**, 176, 1133-1141		6
916	Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. **2011**, 57, 422-31		111
915	The role of phosphorus in the development and progression of vascular calcification. **2011**, 58, 826-34		110
914	Bone mineral density and parathyroid function in patients on maintenance hemodialysis. **2011**, 43, 191-201		11
913	Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?. **2011**, 26, 853-65		23
912	Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. **2011**, 15, 877-83		36
911	Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. **2011**, 12, 56		11

910	Extensive vascular calcification in diabetic uremic patient. **2011**, 40, E1-E1		
909	How the latest evidence from clinical research informs patient care. **2011**, 40, 467-470		
908	Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. *Nephrology Dialysis Transplantation*, **2011**, 26, 3349-57	4.3	51
907	Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay. *Nephrology Dialysis Transplantation*, **2011**, 26, 665-70	4.3	38
906	Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrology Dialysis Transplantation*, **2011**, 26, 3537-43	4.3	87
905	Capillary rarefaction in advanced chronic kidney disease is associated with high phosphorus and bicarbonate levels. *Nephrology Dialysis Transplantation*, **2011**, 26, 3529-36	4.3	28
904	Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. *Nephrology Dialysis Transplantation*, **2011**, 26, 2250-6	4.3	68
903	Iron and vascular calcification. Is there a link?. *Nephrology Dialysis Transplantation*, **2011**, 26, 1137-45	4.3	32
902	Prevention of vascular calcification: is pyrophosphate therapy a solution?. **2011**, 79, 490-3		15
901	Breast arterial calcification: a marker of medial vascular calcification in chronic kidney disease. **2011**, 6, 377-82		56
900	Is coronary artery calcification associated with vertebral bone density in nondialyzed chronic kidney disease patients?. **2011**, 6, 1456-62		17
899	The relationship between epicardial adipose tissue and malnutrition, inflammation, atherosclerosis/calcification syndrome in ESRD patients. **2011**, 6, 1920-5		50
898	Association of severity of conjunctival and corneal calcification with all-cause 1-year mortality in maintenance haemodialysis patients. *Nephrology Dialysis Transplantation*, **2011**, 26, 1016-23	4.3	13
897	Soft bone - hard arteries: a link?. *Kidney and Blood Pressure Research*, **2011**, 34, 203-8	3.1	18
896	Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. **2011**, 2, 265-78		19
895	Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. **2011**, 117, c83-8		8
894	Low iPTH can predict vascular and coronary calcifications in patients undergoing peritoneal dialysis. **2011**, 117, c113-9		11
893	Different effect of IgA nephropathy and polycystic kidney disease on arterial stiffness. *Kidney and Blood Pressure Research*, **2011**, 34, 158-66	3.1	9

892	Does uremia cause vascular dysfunction?. *Kidney and Blood Pressure Research*, **2011**, 34, 284-90	3.1	99
891	Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis. **2011**, 6, 303-10		50
890	Vascular calcification in chronic renal failure: what have we learned from animal studies?. **2011**, 108, 249-64		69
889	Vascular and valvular calcification in chronic peritoneal dialysis patients. **2011**, 2011, 198045		17
888	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. *Nephrology Dialysis Transplantation*, **2011**, 26, 1319-26	4.3	38
887	n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. **2011**, 6, 563-576		4
886	Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 387-95	12.7	172
885	Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease. **2011**, 33, 866-74		18
884	Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study. **2011**, 45, 196-205		3
883	Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. **2011**, 50, 799-805		8
882	Superficial temporal artery calcification in patients with end-stage renal disease: Association with vascular risk factors and ischemic cerebrovascular disease. **2011**, 21, 215-20		0
881	Clinical Significance of FGF-23 in Patients with CKD. **2011**, 2011, 364890		30
880	Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. **2011**, 1, 122-129		23
879	Effect of medial calcification on vascular function in uremia. **2011**, 301, F78-83		26
878	The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. **2011**, 2011, 269060		10
877	Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. **2012**, 123, 399-416		77
876	Mechanisms and clinical consequences of vascular calcification. **2012**, 3, 95		77
875	Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. **2012**, 5, i52-i61		63

874	Methods for assessing arterial stiffness: technical considerations. **2012**, 21, 655-60		53
873	Vascular imaging in chronic kidney disease. **2012**, 21, 382-8		28
872	FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. **2012**, 122, 2543-53		301
871	Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. **2012**, 7, 965-73		52
870	Cinacalcet: will it play a role in reducing cardiovascular events?. **2012**, 8, 357-70		2
869	Uremia induces functional incompetence of bone marrow-derived stromal cells. *Nephrology Dialysis Transplantation*, **2012**, 27, 218-25	4.3	70
868	Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. *Nephrology Dialysis Transplantation*, **2012**, 27, 1957-66	4.3	126
867	Ankle--brachial index, vascular calcifications and mortality in dialysis patients. *Nephrology Dialysis Transplantation*, **2012**, 27, 318-25	4.3	76
866	MicroRNAs that target Ca(2+) transporters are involved in vascular smooth muscle cell calcification. **2012**, 92, 1250-9		56
865	Role of arterial stiffness in cardiovascular disease. **2012**, 1,		165
864	Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. **2012**, 82, 34-44		100
863	Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. **2012**, 287, 25706-14		47
862	Vitamin K status and vascular calcification: evidence from observational and clinical studies. **2012**, 3, 158-65		79
861	Vitamin K intake and status are low in hemodialysis patients. **2012**, 82, 605-10		121
860	Meeting Nutritional Goals for Children Receiving Maintenance Dialysis. **2012**, 377-437		
859	Association between diastolic dysfunction by color tissue Doppler imaging and vascular calcification on plain radiographs in dialysis patients. *Kidney and Blood Pressure Research*, **2012**, 35, 619-26	3.1	5
858	Effect of vascular comorbidities on survival of type 2 diabetes patients on renal replacement therapy. **2012**, 36, 509-15		2
857	Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review. *Nephrology Dialysis Transplantation*, **2012**, 27, 276-92	4.3	70

856	Multimodality vascular imaging in CKD: divergence of risk between measured parameters. *Nephrology Dialysis Transplantation*, **2012**, 27, 1004-12	4.3	11
855	Clinical application of calcium modeling in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 10-3	4.3	6
854	Optimizing the dialysate calcium concentration in bicarbonate haemodialysis. *Nephrology Dialysis Transplantation*, **2012**, 27, 2489-96	4.3	23
853	Cardiac findings at necropsy in patients with chronic kidney disease maintained on chronic hemodialysis. **2012**, 91, 165-178		9
852	Current concepts and management strategies in chronic kidney disease-mineral and bone disorder. **2012**, 105, 479-85		14
851	Vascular calcification in South African dialysis patients: ethnic variation, prevalence, detection and haemodynamic correlates. *Nephrology*, **2012**, 17, 607-15	2.2	9
850	Arterial calcification and bone physiology: role of the bone-vascular axis. **2012**, 8, 529-43		201
849	Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients. **2012**, 44, 1193-9		15
848	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. **2012**, 44, 1169-75		8
847	Relationship between glucose exposure via peritoneal dialysis solutions and coronary artery calcification in non-diabetic peritoneal dialysis patients. **2012**, 44, 1847-53		8
846	Study on the relationship between serum 25-hydroxyvitamin D levels and vascular calcification in hemodialysis patients with consideration of seasonal variation in vitamin D levels. **2012**, 220, 563-8		11
845	Animal models of vascular calcification. **2012**, 222, 574-5; author reply 576		1
844	The risk for medial arterial calcification in CKD. **2012**, 7, 275-9		36
843	Medical options to fight mortality in end-stage renal disease: a review of the literature. *Nephrology Dialysis Transplantation*, **2012**, 27, 4298-307	4.3	20
842	Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. **2012**, 22, 139-42		22
841	Test characteristics of the ankle-brachial index and ankle-brachial difference for medial arterial calcification on X-ray in type 1 diabetes. **2012**, 56, 721-7		45
840	Association between vascular calcification scores on plain radiographs and fatty acid contents of erythrocyte membrane in hemodialysis patients. **2012**, 22, 58-66		11
839	Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. **2012**, 120, c132-8		34

838	Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence. **2013**, 76, 560-72	20
837	Vitamin D receptor activation and prevention of arterial ageing. **2012**, 22, 547-52	13
836	Preexisting venous calcification prior to dialysis vascular access surgery. **2012**, 25, 592-5	25
835	Arterial stiffness and pulse pressure in CKD and ESRD. **2012**, 82, 388-400	240
834	Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells. **2012**, 425, 39-44	53
833	Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. **2012**, 26, 155-66	106
832	Prevalence and progression of cardiovascular calcifications in peritoneal dialysis patients: A prospective study. **2012**, 51, 332-7	19
831	Risk factors associated with brachial-ankle pulse wave velocity among peritoneal dialysis patients in Macao. **2012**, 13, 143	13
830	Osteoporosis--a risk factor for cardiovascular disease?. **2012**, 8, 587-98	118
829	Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. **2012**, 82, 19-25	51
828	Chronic kidney diseaseEhineral bone disorders in diabetic kidney disease. **2012**, 1, 134-137	
827	Survival in patients with poorly compressible leg arteries. **2012**, 59, 400-7	54
826	Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. **2012**, 32, 495-502	31
825	No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. **2012**, 362, 149-56	24
824	Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient. **2012**, 2, 125-133	23
823	Medical and Surgical Management (Including Diet). **2012**, 10, 174-183	2
822	Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder. **2012**, 10, 119-127	2
821	Carotid plaque, carotid intima-media thickness, and coronary calcification equally discriminate prevalent cardiovascular disease in kidney disease. **2012**, 36, 342-7	23

820	The malnutrition-inflammation-depression-arteriosclerosis complex is associated with an increased risk of cardiovascular disease and all-cause death in chronic hemodialysis patients. **2012**, 122, 44-52		20
819	Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. **2012**, 60, 641-54		64
818	Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. *PLoS ONE*, **2012**, 7, e36175	3.7	22
817	Inflammation disrupts the LDL receptor pathway and accelerates the progression of vascular calcification in ESRD patients. *PLoS ONE*, **2012**, 7, e47217	3.7	19
816	Abdominal aortic calcification is associated with diastolic dysfunction, mortality, and nonfatal cardiovascular events in maintenance hemodialysis patients. **2012**, 27, 870-5		19
815	Porcelain heart: rapid progression of cardiac calcification in a patient with hemodialysis. **2012**, 20, 193-6		7
814	The Relationship between Epicardial Adipose Tissue and Coronary Artery Calcification in Peritoneal Dialysis Patients. **2012**, 2, 43-51		25
813	The mechanism of vascular calcification - a systematic review. **2012**, 18, RA1-11		115
812	Prognostic value of arterial pulse wave velocity in peritoneal dialysis patients. **2012**, 35, 127-33		31
811	The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. *Journal of Bone and Mineral Research*, **2012**, 27, 474-85	6.3	81
810	Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification. **2012**, 81, 256-65		28
809	Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. **2012**, 17, 211-20		17
808	Vascular calcification: pathophysiology and risk factors. **2012**, 14, 228-37		119
807	Dialysis type may predict carotid intima media thickness and plaque presence in end-stage renal disease patients. **2012**, 29, 370-82		9
806	Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. **2012**, 27, 135-42		40
805	High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. **2012**, 16, 421-6		18
804	Persistently low intact parathyroid hormone levels predict a progression of aortic arch calcification in incident hemodialysis patients. **2012**, 16, 433-41		12
803	Vitamin d and stage 5 chronic kidney disease: a new paradigm?. **2012**, 25, 50-8		10

802	Haemodialysis and the risk of stroke: A population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. *Nephrology*, **2012**, 17, 243-8	2.2	19
801	Osteopontin upregulation in atherogenesis is associated with cellular oxidative stress triggered by the activation of scavenger receptors. **2012**, 43, 102-11		20
800	Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. **2012**, 59, 636-44		27
799	Cardiovascular risk assessment in children following kidney transplantation. **2012**, 16, 564-76		17
798	Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. *Nephrology*, **2012**, 17, 433-44	2.2	36
797	Integration of clinical and imaging data to predict death in hemodialysis patients. **2013**, 17, 12-8		9
796	Malnutrition, a new inducer for arterial calcification in hemodialysis patients?. **2013**, 11, 66		12
795	Regulatory circuits controlling vascular cell calcification. **2013**, 70, 3187-97		23
794	Is chronic kidney disease an independent risk factor for mortality in breast cancer?. **2013**, 184, 260-4		8
793	Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. **2013**, 14, 122		33
792	Abdominal aortic calcification is not superior over other vascular calcification in predicting mortality in hemodialysis patients: a retrospective observational study. **2013**, 14, 120		22
791	Novel application of □E-sodium fluoride an old tracer to a clinically neglected condition. **2013**, 20, 506-9		1
790	Association of linear □E-sodium fluoride accumulation in femoral arteries as a measure of diffuse calcification with cardiovascular risk factors: a PET/CT study. **2013**, 20, 569-77		63
789	Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease. **2013**, 17, 365-71		30
788	The lipid story in chronic kidney disease: a long story with a happy end?. **2013**, 45, 1273-87		4
787	Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis. **2013**, 28, 308-15		13
786	Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. **2013**, 39, 82-9		18
785	Bone mineral density in patients with predialysis chronic kidney disease. **2013**, 35, 1105-11		15

784	Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?. *Nephrology Dialysis Transplantation*, **2013**, 28, 2923-8	4.3	4
783	A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients. **2013**, 14, 221		20
782	Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients. **2013**, 17, 882-9		10
781	Dysurische Beschwerden und Flankenschmerz bei dialysepflichtiger Patientin mit Diabetes mellitus. **2013**, 8, 516-518		
780	Cardiovascular Calcifications in Old Age: Mechanisms and Clinical Implications. **2013**, 2, 255-267		7
779	Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. **2013**, 38, 158-67		56
778	Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. *Kidney and Blood Pressure Research*, **2013**, 37, 68-83	3.1	21
777	Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients. **2013**, 17, 483-92		5
776	Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. **2013**, 34, 1807-17		124
775	Arterial micro-calcification of vascular access is associated with aortic arch calcification and arterial stiffness in hemodialysis patients. **2013**, 26, 216-22		13
774	Phosphate is a vascular toxin. **2013**, 28, 583-93		58
773	Association of serum fetuin-A and fetuin-A gene polymorphism in relation to mineral and bone disorders in patients with chronic kidney disease. **2013**, 14, 337-352		2
772	Inhibitors of tissue-nonspecific alkaline phosphatase: design, synthesis, kinetics, biomineralization and cellular tests. **2013**, 21, 7981-7		27
771	Chronic kidney disease: the "perfect storm" of cardiometabolic risk illuminates genetic diathesis in cardiovascular disease. **2013**, 62, 799-801		5
770	Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. **2013**, 23, 411-21		33
769	Vitamin D hormone system and diabetes mellitus: Lessons from selective activators of vitamin D receptor and diabetes mellitus. **2013**, 60, 87-95		0
768	Arterial calcification: friend or foe?. **2013**, 167, 322-7		44
767	Calcium-phosphorus product concentration is a risk factor of coronary artery disease in metabolic syndrome. **2013**, 229, 253-7		8

766	The value of Doppler waveform analysis in predicting major lower extremity amputation among dialysis patients treated for diabetic foot ulcers. **2013**, 100, 181-8		13
765	Echocardiographic integrated backscatter for assessing reduction of aortic valve calcifications by R-568 in a rat model of chronic kidney disease. **2013**, 39, 2075-83		4
764	[EVOLVE: between disappointment and optimism]. **2013**, 9, 241-5		0
763	[Vitamin D hormone system and diabetes mellitus: lessons from selective activators of vitamin D receptor and diabetes mellitus]. **2013**, 60, 87-95		1
762	Reprint of: Vitamin D receptor activation and prevention of arterial ageing. **2013**, 23 Suppl 1, S31-6		2
761	Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism. **2013**, 33, 93-105		37
760	Sodium thiosulfate protects human aortic smooth muscle cells from osteoblastic transdifferentiation via high-level phosphate. **2013**, 29, 587-93		6
759	Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. **2013**, 14, 22		26
758	Management of Calcium and Bone Disease in Renal Patients. **2013**, 3073-3086		
757	Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. **2013**, 98, 1084-92		52
756	Mechanistic insights into vascular calcification in CKD. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 179-89	12.7	260
755	Breast Arterial Calcification: a New Marker of Cardiovascular Risk?. **2013**, 7, 126-135		32
754	Bone alkaline phosphatase in CKD-mineral bone disorder. **2013**, 62, 810-22		81
753	Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. **2013**, 83, 1042-51		141
752	Cardiovascular Complications in Patients with Renal Disease. **2013**, 687-700		
751	Functional interaction of osteogenic transcription factors Runx2 and Vdr in transcriptional regulation of Opn during soft tissue calcification. **2013**, 183, 60-8		21
750	Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients. **2013**, 17, 30-4		1
749	Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. *Nephrology Dialysis Transplantation*, **2013**, 28, 3024-30	4.3	93

748	COSMOS: the dialysis scenario of CKD-MBD in Europe. *Nephrology Dialysis Transplantation*, **2013**, 28, 1922-35	4.3	57
747	Renale osteodystrophie. **2013**, 163, 403-8		3
746	Osteopontin: an emerging therapeutic target in uraemic vascular disease. **2013**, 98, 332-3		6
745	Vascular calcification--is aldosterone a culprit?. *Nephrology Dialysis Transplantation*, **2013**, 28, 1080-4	4.3	58
744	Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. *Nephrology Dialysis Transplantation*, **2013**, 28, 869-78	4.3	127
743	Diagnosis of Arterial Media Calcification in Chronic Kidney Disease. **2013**, 3, 89-95		8
742	Prevention and Treatment of CKD-MBD. **2013**, 5, 773-4		2
741	Calcium, Phosphate, PTH, Vitamin D and FGF-23 in Chronic Kidney Disease. **2013**, 263-283		2
740	Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline. **2013**, 124, 1-9		25
739	The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. **2013**, 123, 165-72		9
738	Hemodialysis-induced acute myocardial dyssynchronous impairment in children. **2013**, 123, 83-92		18
737	Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients. **2013**, 124, 89-93		5
736	Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-B and down-regulating IGF1R expression. **2013**, 34, 480-6		16
735	Vascular calcifications, arterial aging and arterial remodeling in ESRD. **2013**, 35, 16-21		26
734	Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease. **2013**, 36, 17-20		20
733	Quantitative analysis of abdominal aortic calcification in CKD patients without dialysis therapy by use of the Agatston score. *Kidney and Blood Pressure Research*, **2013**, 38, 196-204	3.1	14
732	Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. *Journal of Bone and Mineral Research*, **2013**, 28, 2523-34	6.3	23
731	Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis. **2013**, 29, 109-15		2

730	Vascular calcification in end-stage renal disease. **2013**, 17 Suppl 1, S17-21		54
729	ATP and arterial calcification. **2013**, 43, 405-12		16
728	Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. *Nephrology*, **2013**, 18, 777-82	2.2	21
727	Fibroblast growth factor 23 is a predictor of aortic artery calcification in maintenance hemodialysis patients. **2013**, 35, 660-6		10
726	Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. **2013**, 84, 1145-53		44
725	Mechanisms of arterial calcifications and consequences for cardiovascular function. **2013**, 3, 442-445		36
724	Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review. **2013**, 14, 410-5		4
723	Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. **2013**, 7, 25-33		10
722	The prognostic value of abdominal aortic calcification in peritoneal dialysis patients. **2013**, 10, 617-23		16
721	Patient education for phosphorus management in chronic kidney disease. **2013**, 7, 379-90		59
720	Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. **2013**, 20, 538-47		28
719	INHIBITORY EFFECT OF IRON ADMINISTRATION ON VASCULAR CALCIFICATION IN UREMIC RATS. **2013**, 59, 340-346		
718	TGF-□prevents phosphate-induced osteogenesis through inhibition of BMP and Wnt/□catenin pathways. *PLoS ONE*, **2014**, 9, e89179	3.7	36
717	Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. *PLoS ONE*, **2014**, 9, e100688	3.7	49
716	Circulating endothelial cells and chronic kidney disease. **2014**, 2014, 364738		7
715	Risk Factors of Arterial Damage Assessed by ABI and baPWV among Hemodialysis Patients in Macau. **2014**, 2014, 1-6		2
714	5-aza-2'-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells. **2014**, 21, 463-76		30
713	Role of Krᵽpel-like factor 4 and its binding proteins in vascular disease. **2014**, 21, 402-13		34

712	5(th) Asian PAD Workshop. **2014**, 7, 199-218		3
711	Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. **2014**, 86, 286-93		51
710	Markers of increased cardiovascular risk in patients with chronic kidney disease. **2014**, 13, 135		33
709	Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. **2014**, 15, 145		76
708	Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. **2014**, 15, 168		37
707	Vascular calcification is coupled with phenotypic conversion of vascular smooth muscle cells through Klf5-mediated transactivation of the Runx2 promoter. **2014**, 34, e00148		24
706	An update on coronary artery disease and chronic kidney disease. **2014**, 2014, 767424		50
705	Vitamin k dependent proteins and the role of vitamin k2 in the modulation of vascular calcification: a review. **2014**, 29, 172-7		45
704	Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease. **2014**, 2014, 381082		24
703	Resistance to erythropoiesis-stimulating agents is associated with arterial microcalcification in early hemodialysis patients. **2014**, 2014, 731296		2
702	Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events. **2014**, 4, 58-62		1
701	Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. *Nephrology Dialysis Transplantation*, **2014**, 29, 1385-90	4.3	73
700	Cinacalcet hydrochloride for the treatment of hyperparathyroidism. **2014**, 2, 851-863		
699	Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control. **2014**, 34, 648-59		14
698	When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. **2014**, 34, 612-25		45
697	Vascular calcification in long-term kidney transplantation. *Nephrology*, **2014**, 19, 251-6	2.2	7
696	Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. **2014**, 36, 131-8		7
695	Extraosseous calcification in end-stage renal disease: from visceral organs to vasculature. **2014**, 27, 477-87		5

694	Calcification of the internal pudendal artery and development of erectile dysfunction in adenine-induced chronic kidney disease: a sentinel of systemic vascular changes. **2014**, 11, 2449-65		7
693	Impact of arterial microcalcification of the vascular access on cardiovascular mortality in hemodialysis patients. **2014**, 18, 54-61		9
692	The relationship between neutrophil-to-lymphocyte ratio and vascular calcification in end-stage renal disease patients. **2014**, 18, 47-53		42
691	Anti-osteoporotic drugs and vascular calcification: the bidirectional calcium traffic. **2014**, 51, 37-49		4
690	Low hip bone mineral density predicts mortality in maintenance hemodialysis patients: a five-year follow-up study. **2014**, 37, 33-8		15
689	Aortic arch calcification predicts cardiovascular and all-cause mortality in maintenance hemodialysis patients. *Kidney and Blood Pressure Research*, **2014**, 39, 658-67	3.1	23
688	Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients. **2014**, 60, 462-70		43
687	Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease. **2014**, 24, 143-50		14
686	Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?. **2014**, 46, 175-82		20
685	FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. **2014**, 46, 121-8		15
684	Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. **2014**, 32, 636-44		4
683	Regulation of mineral metabolism by lithium. **2014**, 466, 467-75		13
682	Suppressive effects of iron overloading on vascular calcification in uremic rats. *Journal of Nephrology*, **2014**, 27, 135-42	4.8	13
681	Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials. **2014**, 30, 99-108		3
680	Medial vascular calcification revisited: review and perspectives. **2014**, 35, 1515-25		411
679	Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. **2014**, 101, 256-65		55
678	Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. **2014**, 85, 1103-11		123
677	Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. **2014**, 85, 668-76		44

676	miR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smooth muscle cells in a high-phosphate environment. **2014**, 322, 302-12		48
675	Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. **2014**, 85, 142-50		144
674	Dietary L-lysine prevents arterial calcification in adenine-induced uremic rats. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1954-65	12.7	38
673	Effect of serum fibroblast growth factor-23, matrix Gla protein and Fetuin-A in predicting osteoporosis in maintenance hemodialysis patients. **2014**, 18, 427-33		3
672	Phosphate: an old bone molecule but new cardiovascular risk factor. **2014**, 77, 39-54		17
671	Physical activity in chronic kidney disease: a plausible approach to vascular calcification?. *Kidney and Blood Pressure Research*, **2014**, 39, 154-63	3.1	1
670	Impact of aldosterone on osteoinductive signaling and vascular calcification. **2014**, 128, 40-5		36
669	The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. **2014**, 21, 480-8		33
668	Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. **2014**, 80, 508-15		20
667	Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. **2014**, 18, 353-60		23
666	[Another story of sevelamer]. **2014**, 10, 421-6		0
665	A current understanding of vascular calcification in CKD. **2014**, 307, F891-900		200
664	[Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent]. **2014**, 10, 441-50		5
663	Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. **2014**, 13, 551-61		40
662	Assessment of potential biomarkers of subclinical vitamin K deficiency in patients with end-stage kidney disease. **2014**, 1, 13		22
661	Arterial location-specific calcification at the carotid artery and aortic arch for chronic kidney disease, diabetes mellitus, hypertension, and dyslipidemia. *Calcified Tissue International*, **2014**, 95, 267-74	3.9	10
660	Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. **2014**, 306, F1418-28		108
659	Role of local versus systemic vitamin D receptors in vascular calcification. **2014**, 34, 146-51		28

658	QT dispersion predicts mortality and correlates with both coronary artery calcification and atherosclerosis in hemodialysis patients. **2014**, 46, 599-605		8
657	Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. **2014**, 233, 91-6		15
656	Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. **2014**, 15, 1475-88		5
655	Phosphorus and the kidney: What is known and what is needed. **2014**, 5, 98-103		14
654	Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification. **2014**, 78, 2339-46		41
653	Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification. **2015**, 309, F967-79		28
652	Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy. **2015**, 45, 976-85		66
651	Best practice for diabetic patients on hemodialysis 2012. **2015**, 19 Suppl 1, 40-66		44
650	Vascular calcification on plain radiographs is related with the severity of lesions detected by coronary angiography in dialysis patients. **2015**, 235, 135-44		8
649	Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. **2015**, 23, 109-18		20
648	Calcified carotid artery plaques predict cardiovascular outcomes in the elderly. **2015**, 33, 810-7; discussion 817		10
647	Impact of Dialysate Calcium Concentration on Clinical Outcomes in Incident Hemodialysis Patients. **2015**, 94, e1694		11
646	Disturbances in Bone Largely Predict Aortic Calcification in an Alternative Rat Model Developed to Study Both Vascular and Bone Pathology in Chronic Kidney Disease. *Journal of Bone and Mineral Research*, **2015**, 30, 2313-24	6.3	15
645	Association Between Vascular Access Dysfunction and Subsequent Major Adverse Cardiovascular Events in Patients on Hemodialysis: A Population-Based Nested Case-Control Study. **2015**, 94, e1032		13
644	Epicardial adipose tissue in patients with end-stage renal disease on haemodialysis. **2015**, 24, 517-24		8
643	Aortic Artery and Cardiac Valve Calcification are Associated with Mortality in Chinese Hemodialysis Patients: A 3.5 Years Follow-up. **2015**, 128, 2764-71		11
642	Mineral and bone disorder after kidney transplantation. **2015**, 5, 231-42		18
641	Characterisation of calcium phosphate crystals on calcified human aortic vascular smooth muscle cells and potential role of magnesium. *PLoS ONE*, **2015**, 10, e0115342	3.7	50

640	Mineral Composition of Phosphate-Induced Calcification in a Rat Aortic Tissue Culture Model. **2015**, 22, 1197-206		14
639	Vascular effects of advanced glycation end-products: content of immunohistochemically detected AGEs in radial artery samples as a predictor for arterial calcification and cardiovascular risk in asymptomatic patients with chronic kidney disease. **2015**, 2015, 153978		16
638	Low Magnesium Levels and FGF-23 Dysregulation Predict Mitral Valve Calcification as well as Intima Media Thickness in Predialysis Diabetic Patients. **2015**, 2015, 308190		17
637	Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. **2015**, 2015, 515606		21
636	Inflammation and Hypertension. **2015**, 141-156		2
635	The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. **2015**, 6, 84-96		31
634	Arterial stiffness and increased cardiovascular risk in chronic kidney disease. **2015**, 47, 1157-64		15
633	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. **2015**, 10, 791-9		52
632	Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature. **2015**, 13, 206-15		43
631	Early and Late Stages of Chronic Kidney Disease in Relation to Arterial Changes. **2015**, 169-180		
630	Use of sevelamer in chronic kidney disease: beyond phosphorus control. **2015**, 35, 207-217		10
629	Vitamin D, phosphate, and vasculotoxicity. **2015**, 93, 1077-82		28
628	Fibroblast Growth Factor-23 and Vitamin D Metabolism in Subjects with eGFR ≥60 ml/min/1.73 m² **2015**, 130, 119-26		6
627	Vascular Calcification Progression Is an Independent Predictor of Mortality in Patients on Haemodialysis. **2015**, 130, 169-74		8
626	Breast arterial calcifications: a systematic review and meta-analysis of their determinants and their association with cardiovascular events. **2015**, 239, 11-20		72
625	Erythropoiesis-stimulating agents: dose and mortality risk. **2015**, 25, 164-8		10
624	Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. **2015**, 67, 683-9		133
623	NH4Cl Treatment Prevents Tissue Calcification in Klotho Deficiency. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 2423-33	12.7	42

622	Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. **2015**, 10, 131-142		1
621	Renal haemodynamics and severity of carotid atherosclerosis in hypertensive patients with and without impaired renal function. **2015**, 25, 160-6		29
620	Physiological Actions of PTH and PTHrP IV. **2015**, 187-201		0
619	Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats. **2015**, 87, 1141-52		41
618	Arteriosclerosis, bone biology, and calciotropic hormone signaling: learning the ABCs of disease in the bone-vascular axis. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 243-5	12.7	6
617	Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. *Journal of Nephrology*, **2015**, 28, 593-602	4.8	10
616	Upper limb vascular calcification score as a predictor of mortality in diabetic hemodialysis patients. **2015**, 61, 1529-37		13
615	BMP type I receptor inhibition attenuates endothelial dysfunction in mice with chronic kidney disease. **2015**, 87, 128-36		18
614	Oxidative stress and inflammation associated with decreased fibrinolysis as an early marker for peripheral vascular disease stratification: A clinical study. **2015**, 8, 24-30		
613	Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. **2015**, 130, 229-38		6
612	Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort Study. **2015**, 46, 2075-80		59
611	Changes in pulse pressure during hemodialysis treatment and survival in maintenance dialysis patients. **2015**, 10, 1179-91		18
610	Runx2 Expression in Smooth Muscle Cells Is Required for Arterial Medial Calcification in Mice. **2015**, 185, 1958-69		78
609	Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. **2015**, 482, 21-6		6
608	FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. **2015**, 5, 8304		29
607	Breast arterial calcifications and their association with incident cardiovascular disease and diabetes: the Prospect-EPIC cohort. **2015**, 65, 859-860		23
606	[The matrix-gla protein awakening may lead to the demise of vascular calcification]. **2015**, 11, 191-200		3
605	Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. **2015**, 13, 489-99		2

604	Hyperphosphate-Induced Myocardial Hypertrophy through the GATA-4/NFAT-3 Signaling Pathway Is Attenuated by ERK Inhibitor Treatment. **2015**, 5, 79-88		21
603	Rat aortic smooth muscle cells cultured on hydroxyapatite differentiate into osteoblast-like cells via BMP-2-SMAD-5 pathway. *Calcified Tissue International*, **2015**, 96, 359-69	3.9	21
602	Chronic Kidney Disease is associated with an increase of Intimal Dendritic cells in a comparative autopsy study. **2015**, 12, 26		8
601	Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?. **2015**, 26, 2165-74		41
600	Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. **2015**, 54, 1587-95		6
599	Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. *Nephrology Dialysis Transplantation*, **2015**, 30, 1345-56	4.3	81
598	Pathophysiology of Vascular Calcification. **2015**, 13, 372-80		65
597	Fifty shades of gray: Bone disease in renal transplantation. **2015**, 24, 225-232		1
596	Arterial Stiffness: A Novel Risk Factor for Kidney Injury Progression?. **2015**, 28, 958-65		39
595	Chronic kidney disease in congenital heart disease patients: a narrative review of evidence. **2015**, 2, 27		40
594	Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. **2015**, 6, 7495		285
593	Vascular calcification in predialysis CKD: common and deadly. **2015**, 10, 551-3		9
592	Use of sevelamer in chronic kidney disease: beyond phosphorus control. **2015**, 35, 207-17		12
591	Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. *Journal of Bone and Mineral Research*, **2015**, 30, 824-36	6.3	135
590	The clinical significance of medial arterial calcification in end-stage renal disease in women. **2015**, 87, 195-9		38
589	Chronic kidney disease and cardiovascular complications. **2015**, 20, 259-72		128
588	Evidence for the prevention and treatment of stroke in dialysis patients. **2015**, 28, 35-47		35
587	Magnesium Attenuates Phosphate-Induced Deregulation of a MicroRNA Signature and Prevents Modulation of Smad1 and Osterix during the Course of Vascular Calcification. **2016**, 2016, 7419524		41

586	Mechanisms of Vascular Calcification: The Pivotal Role of Pyruvate Dehydrogenase Kinase 4. **2016**, 31, 52-61		22
585	Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients. *PLoS ONE*, **2016**, 11, e0150145	3.7	8
584	High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. *PLoS ONE*, **2016**, 11, e0151508	3.7	22
583	Indoxyl Sulfate Enhance the Hypermethylation of Klotho and Promote the Process of Vascular Calcification in Chronic Kidney Disease. **2016**, 12, 1236-1246		48
582	Coronary Calcium Score May Replace Cardiovascular Risk Factors as Primary Risk Stratification Tool Before Kidney Transplantation. **2016**, 100, 2177-87		9
581	Coronary Revascularization in Chronic and End-Stage Renal Disease: A Systematic Review and Meta-analysis. **2016**, 23, e16-28		13
580	Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1□Hydroxylase Expression in Vascular Smooth Muscle Cells. *Journal of Bone and Mineral Research*, **2016**, 31, 1865-1876	6.3	20
579	Both pelvic radiography and lateral abdominal radiography correlate well with coronary artery calcification measured by computed tomography in hemodialysis patients: A cross-sectional study. **2016**, 20, 399-406		10
578	Porphyromonas gingivalis Lipopolysaccharide Stimulation of Vascular Smooth Muscle Cells Activates Proliferation and Calcification. **2016**, 87, 828-36		14
577	Aortic Arch Calcification Predicts Patency Loss of Arteriovenous Fistula in End-Stage Renal Disease Patients. **2016**, 6, 24943		8
576	Vitamin K-Dependent Protein Activity and Incident Ischemic Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. **2016**, 36, 1037-42		17
575	Vitamin K2 regression aortic calcification induced by warfarin via Gas6/Axl survival pathway in rats. **2016**, 786, 10-18		11
574	Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients. **2016**, 27, 2717-2726		18
573	Nutrition in Cardioskeletal Health. **2016**, 7, 544-55		5
572	Phosphate induces formation of matrix vesicles during odontoblast-initiated mineralization in vitro. **2016**, 52-54, 284-300		30
571	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. **2016**, 15, 22		19
570	Facile preparation and evaluation of allylamine hydrochloride-based porous hydrogel without calcium and aluminum: an alternative candidate of phosphate binder. **2016**, 73, 3371-3384		1
569	Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. **2016**, 36, 24-32		19

568	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. **2016**, 92, 50-57		27
567	Intermittent Haemoptysis due to an Aortobronchial Fistula in a Warmblood Mare. **2016**, 155, 213-217		2
566	Klotho Prevents Translocation of NFB. **2016**, 101, 119-50		23
565	Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. **2016**, 48, 2043-2050		22
564	Semiquantitative assessment of tibial artery calcification by computed tomography angiography and its ability to predict infrapopliteal angioplasty outcomes. **2016**, 64, 1335-1343		23
563	Curcumin attenuates osteogenic differentiation and calcification of rat vascular smooth muscle cells. **2016**, 420, 151-60		23
562	MicroRNA-34b/c inhibits aldosterone-induced vascular smooth muscle cell calcification via a SATB2/Runx2 pathway. **2016**, 366, 733-746		27
561	Large animal models of cardiovascular disease. **2016**, 34, 113-32		67
560	High cut-off dialysis in chronic haemodialysis patients reduces serum procalcific activity. *Nephrology Dialysis Transplantation*, **2016**, 31, 1706-12	4.3	19
559	MICS, an easily ignored contributor to arterial calcification in CKD patients. **2016**, 311, F663-F670		13
558	Assessment of abdominal aortic calcification at different stages of chronic kidney disease. **2016**, 48, 2061-2068		15
557	Low Dentin Matrix Protein 1 Is Associated With Incident Cardiovascular Events in Peritoneal Dialysis Patients. *Journal of Bone and Mineral Research*, **2016**, 31, 2149-2158	6.3	3
556	Molecular Biology of Vitamin D: Genomic and Nongenomic Actions of Vitamin D in Chronic Kidney Disease. **2016**, 51-74		
555	Association between vascular calcification assessed by simple radiography and non-fatal cardiovascular events in hemodialysis patients. **2016**, 12, 503-507		2
554	Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. **2016**, 36, 24-32		8
553	POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification. **2016**, 11, 35		7
552	Gas6 protein: its role in cardiovascular calcification. **2016**, 17, 52		14
551	Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. **2016**, 110, 408-18		61

550	Antiplatelet effects of aspirin in chronic kidney disease patients. **2016**, 14, 375-80		40
549	Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients. **2016**, 31, 6-14		13
548	Impact of deteriorated calcium-phosphate homeostasis on amputation-free survival after endovascular revascularization in patients with critical limb ischemia on hemodialysis. **2016**, 21, 137-43		7
547	Gelatinases promote calcification of vascular smooth muscle cells by up-regulating bone morphogenetic protein-2. **2016**, 470, 287-293		17
546	NFB-sensitive Orai1 expression in the regulation of FGF23 release. **2016**, 94, 557-66		37
545	Complement and Cardiovascular Disease--The Missing Link in Haemodialysis Patients. **2016**, 132, 5-14		19
544	Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. **2016**, 89, 666-74		27
543	Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. **2016**, 118, 535-46		538
542	Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2475-86	12.7	49
541	Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology. **2016**, 9, 176-92		63
540	Clinical imaging of vascular disease in chronic kidney disease. **2016**, 48, 827-37		9
539	Effects of Gingko biloba extract (EGb 761) on vascular smooth muscle cell calcification induced by -glycerophosphate. **2016**, 38, 552-7		9
538	Coronary Artery Calcification Score as A Predictor of All-Cause Mortality and Cardiovascular Outcome in Peritoneal Dialysis Patients. **2016**, 36, 163-70		14
537	Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. **2016**, 452, 38-43		30
536	Aortic Aging in ESRD: Structural, Hemodynamic, and Mortality Implications. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1837-46	12.7	49
535	Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients. **2016**, 20, 416-24		4
534	Vascular Damage and Kidney Transplant Outcomes: An Unfriendly and Harmful Link. **2017**, 354, 7-16		5
533	Impact of renal function impairment assessed by CKD estimated glomerular filtration rate on early and late outcomes after coronary artery bypass grafting. **2017**, 227, 778-787		6

532	Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A´Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. *Kidney International Reports*, **2017**, 2, 380-389	4.1	53
531	Phosphate Binders and Targets Over Decades: Do We have it Right Now?. **2017**, 30, 134-141		7
530	Magnesium prevents phosphate-induced vascular calcification via TRPM7 and Pit-1 in an aortic tissue culture model. **2017**, 40, 562-567		12
529	Vascular inflammation and media calcification are already present in early stages of chronic kidney disease. **2017**, 27, 57-67		36
528	Abdominal aortic calcification on dual-energy X-ray absorptiometry: Methods of assessment and clinical significance. **2017**, 104, 91-100		28
527	Calcification of the splenic, iliac, and breast arteries and risk of all-cause and cardiovascular mortality. **2017**, 259, 120-127		24
526	Vitamin K Antagonist Therapy Is a Risk Factor for Ulcer Development and Death Among Dialyzed Patients. **2017**, 21, 150-156		2
525	Lower serum magnesium is associated with vascular calcification in peritoneal dialysis patients: a cross sectional study. **2017**, 18, 129		33
524	Inhibition of osteo/chondrogenic transformation of vascular smooth muscle cells by MgCl2 via calcium-sensing receptor. **2017**, 35, 523-532		30
523	Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins. **2017**, 313, H1-H13		31
522	Pulse wave velocity is associated with cognitive impairment in hemodialysis patients. **2017**, 131, 1483-1493		10
521	The Role of Emerging Risk Factors in Cardiovascular Outcomes. **2017**, 19, 28		28
520	Chronic Kidney Disease-Mineral and Bone Disorder in Asia. **2017**, 3, 1-7		4
519	Vascular calcification in chronic kidney disease: different bricks in the wall?. **2017**, 91, 808-817		141
518	Novel functions of circulating Klotho. **2017**, 100, 36-40		13
517	The relationship between coronary artery calcium scores and left atrium size in hemodialysis patients. **2017**, 49, 1661-1666		
516	Evaluation of Carotid Ultrasonography Screening Among Kidney Transplant Candidates: A Single-Center, Retrospective Study. **2017**, 3, e135		1
515	Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. **2017**, 7, 2233		23

514	Coronary Plaque Characteristics in Hemodialysis-Dependent Patients as Assessed by Optical Coherence Tomography. **2017**, 119, 1313-1319	14
513	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. **2017**, 2, 635-643	154
512	Imaging for Vascular Calcification. **2017**, 30, 347-352	6
511	Activation of peroxisome proliferator-activated receptor inhibits vascular calcification by upregulating Klotho. **2017**, 13, 467-474	20
510	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. **2017**, 35, 536-543	7
509	Calcification score evaluation in patients listed for renal transplantation. **2017**, 31, e12888	5
508	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. **2017**, 69, 314-322	19
507	Does statins promote vascular calcification in chronic kidney disease?. **2017**, 47, 137-148	48
506	The P2Y nucleotide receptor is an inhibitor of vascular calcification. **2017**, 257, 38-46	14
505	Factors associated with diffusely increased renal uptake of Tc-99m diphosphono-propanedicarboxylic acid on bone scintigraphy in patients with end-stage renal disease. **2017**, 38, 1060-1066	
504	Prevalence of abdominal artery calcification in dialysis patients with end-stage renal disease: a systematic review and meta-analysis. **2017**, 49, 2061-2069	12
503	Warfarin Use and Increased Mortality in End-Stage Renal Disease. **2017**, 46, 249-256	18
502	Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease. **2017**, 633, 50-57	13
501	The association of serum adiponectin with abdominal aortic calcification in Japanese male hemodialysis patients: a cross-sectional observational study. **2017**, 7, 6434	7
500	A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. **2017**, 7, 6858	21
499	Relation Between Calcified Atherosclerosis in the Renal Arteries and Kidney Function (from the Multi-Ethnic Study of Atherosclerosis). **2017**, 120, 1434-1439	5
498	Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. **2017**, 96, e5924	13
497	Magnesium Counteracts Vascular Calcification: Passive Interference or Active Modulation?. **2017**, 37, 1431-1445	52

496	Two-Year Changes in Proteinuria and the Risk of Stroke in the Chinese Population: A Prospective Cohort Study. **2017**, 6,		9
495	Phosphate-Containing Prescription Medications Contribute to the Daily Phosphate Intake in a Third of Hemodialysis Patients. **2017**, 27, 91-96		21
494	Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. **2017**, 100, 87-93		149
493	Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. **2017**, 167, 55-60		6
492	Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1162-1174	12.7	57
491	Arterial calcification: A new perspective?. **2017**, 228, 11-22		32
490	Coronary artery calcification in Korean patients with incident dialysis. **2017**, 21, 367-374		3
489	Design and baseline characteristics of the LANDMARK study. **2017**, 21, 531-537		8
488	Plain pelvic/aorta radiographs as a simple guideline to predict vascular macro-calcifications; one step earlier or a late sign to best weight the enemy of coronary calcification and mortality?. **2017**, 21, 142-144		
487	Oral Health and Mortality in Patients With Chronic Kidney Disease. **2017**, 88, 26-33		20
486	Elevated serum phosphate levels are associated with decreased amputation-free survival after interventions for critical limb ischemia. **2017**, 65, 431-437		3
485	A single gene connects stiffness in glaucoma and the vascular system. **2017**, 158, 13-22		9
484	Vascular Calcification: Current Genetics Underlying This Complex Phenomenon. **2017**, 130, 1113-1121		11
483	Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients. **2017**, 32, 54-59		14
482	Breast Arterial Calcifications on Mammography Do Not Predict Myocardial Ischemia on Myocardial Perfusion Single-Photon Emission Computed Tomography. **2017**, 8, 220-227		7
481	APE1/Ref-1 Inhibits Phosphate-Induced Calcification and Osteoblastic Phenotype Changes in Vascular Smooth Muscle Cells. **2017**, 18,		12
480	Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial. **2017**, 9,		4
479	The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients. **2017**, 2017, 9035193		19

478	Deterioration of Cerebral Oxygenation by Aortic Arch Calcification Progression in Patients Undergoing Hemodialysis: A Cross-Sectional Study. **2017**, 2017, 2852514		8
477	Aortic Arch Calcification as a Predictor of Repeated Arteriovenous Fistula Failure within 1-Year in Hemodialysis Patients. **2017**, 2017, 6728437		2
476	The Involvement of Notch1-RBP-Jk/Msx2 Signaling Pathway in Aortic Calcification of Diabetic Nephropathy Rats. **2017**, 2017, 8968523		6
475	What happens to the heart in chronic kidney disease?. **2017**, 47, 76-82		14
474	A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder. **2017**, 2017, 1659071		3
473	Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. *PLoS ONE*, **2017**, 12, e0179868	3.7	6
472	The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. *PLoS ONE*, **2017**, 12, e0174811	3.7	17
471	Calcium Overload Accelerates Phosphate-Induced Vascular Calcification Via Pit-1, but not the Calcium-Sensing Receptor. **2017**, 24, 716-724		17
470	Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate. **2017**, 3,		3
469	Determinants of the Change in Arterial Stiffness in Peritoneal Dialysis Patients. **2017**, 58, 915-925		4
468	Understanding the Pathophysiology of Nephrocalcinosis. **2017**,		6
467	Pelvic Artery Calcification Score Is a Marker of Vascular Calcification in Male Hemodialysis Patients. **2018**, 22, 509-513		2
466	Inactive Matrix Gla Protein, Arterial Stiffness, and Endothelial Function in African American Hemodialysis Patients. **2018**, 31, 735-741		17
465	Mechanisms of Arterial Calcification: The Role of Matrix Vesicles. **2018**, 55, 425-432		44
464	Abdominal Aortic Calcifications Predict Survival in Peritoneal Dialysis Patients. **2018**, 38, 366-373		9
463	Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. **2018**, 8, 2069		58
462	Impact of dialysis dependence on prognosis in patients with myocardial infarction: An 11-year population-based study. **2018**, 97, e9833		6
461	Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. **2018**, 271, 53-60		37

460	Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease. **2018**, 67, 1855-1863.e1		10
459	Annularity of Aorto-Iliac Arterial Calcification and Risk of All-Cause and Cardiovascular Mortality. **2018**, 11, 1718-1719		6
458	Impaired renal function is associated with adverse outcomes in patients with chest pain discharged from internal medicine wards. **2018**, 53, 57-61		5
457	Long-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration. **2018**, 8, e019900		9
456	Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials. **2018**, 41, 309-319		12
455	Risk of acute coronary syndrome after parathyroidectomy in patients with end-stage renal disease: A population-based cohort study in Taiwan. *Nephrology*, **2018**, 23, 139-147	2.2	5
454	Sex differences in vascular dysfunction and cardiovascular outcomes: The cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study. **2018**, 22, 93-102		9
453	Media sclerosis Mönckeberg affects microcirculation. **2018**, 60, e533-e535		1
452	Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation. **2018**, 31, 37-47		8
451	Diabetes and Vascular Calcification. **2018**, 59-68		
450	Primary media sclerosis Mönckeberg: Diagnostic criteria. **2018**, 60, e205-e208		2
449	Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients. *Kidney International Reports*, **2018**, 3, 185-192	4.1	4
448	Impaired Phosphate Tolerance Revealed With an Acute Oral Challenge. *Journal of Bone and Mineral Research*, **2018**, 33, 113-122	6.3	12
447	High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification. **2018**, 114, 264-275		29
446	Abdominal aorta and pelvic artery calcifications on plain radiographs may predict mortality in chronic kidney disease, hemodialysis and renal transplantation. **2018**, 50, 355-364		11
445	Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/β-catenin signaling. **2018**, 284, 29-36		48
444	Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis. *Calcified Tissue International*, **2018**, 102, 310-320	3.9	15
443	Vascular calcification is not related to serum fetuin-A and osteopontin levels in hemodialysis patients. **2018**, 50, 137-142		12

442	Characterization and assessment of potential microRNAs involved in phosphate-induced aortic calcification. **2018**, 233, 4056-4067		17
441	Rock-Hard Chronic Thrombotic Occlusion and Its Management in Endovascular Interventions. **2018**, 35, 461-468		1
440	Intracranial Carotid Artery Calcification and Effect of Endovascular Stroke Treatment. **2018**, 49, 2961-2968		20
439	Progression of Medial Arterial Calcification in CKD. *Kidney International Reports*, **2018**, 3, 1328-1335	4.1	20
438	Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis. **2018**, 48, 369-377		12
437	Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease. **2018**, 38, 542-558		16
436	Combined effects of hyperphosphatemia and hyperglycemia on the calcification of cultured human aortic smooth muscle cells. **2019**, 17, 863-868		13
435	Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis. *PLoS ONE*, **2018**, 13, e0204526	3.7	12
434	The Bone and Mineral Disorder in Patients Undergoing Chronic Peritoneal Dialysis. **2018**,		
433	Pathophysiology and Treatment of Chronic Kidney Disease Mineral and Bone Disorder. **2018**, 695-704		
432	Management of patients with end-stage renal disease: coronary artery bypass graft surgery versus percutaneous coronary intervention. **2018**, 33, 546-550		4
431	The role of klotho in chronic kidney disease. **2018**, 19, 285		72
430	End-Stage Renal Disease Impairs the Multidirectional Movements of the Common Carotid Artery: Assessment Using Dimensional Speckle-Tracking Carotid Strain Ultrasonography. **2018**, 26, 155-164		1
429	Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts. **2018**, 15, 557-563		9
428	The association between heart rhythm complexity and the severity of abdominal aorta calcification in peritoneal dialysis patients. **2018**, 8, 15627		4
427	Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. **2018**, 2018, 4310379		27
426	Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome. **2018**, 38, 413-419		5
425	FGF23 beyond Phosphotropic Hormone. **2018**, 29, 755-767		28

424	The role of kidney transplantation and phosphate binder use in vitamin K status. *PLoS ONE*, **2018**, 13, e0203157	3.7	29
423	Autophagy Protects From Uremic Vascular Media Calcification. **2018**, 9, 1866		28
422	Mineralo-organic nanoparticles in health and disease: an overview of recent findings. **2018**, 13, 1787-1793		8
421	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 2015-2027	12.7	100
420	An Update on Calciphylaxis. **2018**, 19, 599-608		21
419	Skeletal Variation (SV). **2018**, 737-769		
418	Vitamin D and Renal Disease. **2018**, 445-469		1
417	Polymorphism related to cardiovascular risk in hemodialysis subjects: a systematic review. **2018**, 40, 179-192		1
416	Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond. **2018**, 9, 207		20
415	Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification. **2018**, 22, 519-529		12
414	Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review. **2018**, 10,		46
413	Vitamin D in Vascular Calcification: A Double-Edged Sword?. **2018**, 10,		38
412	In search of the vulnerable patient or the vulnerable plaque: F-sodium fluoride positron emission tomography for cardiovascular risk stratification. **2018**, 25, 1774-1783		19
411	Magnesium Citrate Protects Against Vascular Calcification in an Adenine-induced Chronic Renal Failure Rat Model. *Journal of Cardiovascular Pharmacology*, **2018**, 72, 270-276	3.1	8
410	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. **2018**, 107, 120-126		20
409	Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. **2018**, 31, 487-499		29
408	Vitamin D. **2018**, 549-570		1
407	The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. **2018**, 13, 1373-1380		67

406	The interplay between bone and vessels in pediatric CKD: lessons from a single-center study. **2018**, 33, 1565-1575		10
405	Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism. **2018**, 366, 433-445		10
404	Intimal and medial arterial changes defined by ultra-high-frequency ultrasound: Response to changing risk factors in children with chronic kidney disease. *PLoS ONE*, **2018**, 13, e0198547	3.7	13
403	Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles. *Nephrology Dialysis Transplantation*, **2019**, 34, 992-1000	4.3	20
402	Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study. **2019**, 41, 345-355		3
401	Impact of Abdominal Aortic Calcification on Central Haemodynamics and Decline of Glomerular Filtration Rate in Patients with Chronic Kidney Disease Stages 3 and 4. *Kidney and Blood Pressure Research*, **2019**, 44, 950-960	3.1	3
400	The synergistic action of phosphate and interleukin-6 enhances senescence-associated calcification in vascular smooth muscle cells depending on p53. **2019**, 182, 111124		14
399	Phosphate-induced ORAI1 expression and store-operated Ca entry in aortic smooth muscle cells. **2019**, 97, 1465-1475		14
398	Ginsenoside Rb1 ameliorates CKD-associated vascular calcification by inhibiting the Wnt/-catenin pathway. **2019**, 23, 7088-7098		25
397	Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient. **2019**, 32, 541-552		4
396	Characteristics of coronary artery atherosclerotic plaques in chronic kidney disease: evaluation with coronary CT angiography. **2019**, 74, 731.e1-731.e9		3
395	Wnt1 inhibits vascular smooth muscle cell calcification by promoting ANKH expression. **2019**, 135, 10-21		8
394	Inhibition of vascular smooth muscle cell calcification by vasorin through interference with TGF1 signaling. **2019**, 64, 109414		8
393	METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate. **2019**, 239, 117034		28
392	Aloe-emodin inhibits osteogenic differentiation and calcification of mouse vascular smooth muscle cells. **2019**, 865, 172772		2
391	Pathogenesis and management of vascular calcification in CKD and dialysis patients. **2019**, 32, 553-561		15
390	Indoxyl sulfate-induced calcification of vascular smooth muscle cells via the PI3K/Akt/NF-B signaling pathway. **2019**, 82, 2000-2006		24
389	Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. **2019**, 3, 578-588		13

388	Evaluation of the association of Wnt signaling with coronary artery calcification in patients on dialysis with severe secondary hyperparathyroidism. **2019**, 20, 345		7
387	Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. **2019**, 17, 333-342		6
386	The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. **2019**, 51, 2037-2044		26
385	Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. **2019**, 74, 1823-1838		170
384	Changes in FGF-23, Neutrophil/Platelet Activation Markers, and Angiogenin in Advanced Chronic Kidney Disease and Their Effect on Arterial Stiffness. *Kidney and Blood Pressure Research*, **2019**, 44, 1166-1178	3.1	9
383	The assessment of coronary artery disease in patients with end-stage renal disease. **2019**, 12, 721-734		7
382	Kidney function, proteinuria and breast arterial calcification in women without clinical cardiovascular disease: The MINERVA study. *PLoS ONE*, **2019**, 14, e0210973	3.7	4
381	Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients. **2019**, 51, 527-534		4
380	Greater aortic stiffness is associated with renal dysfunction in participants of the ELSA-Brasil cohort with and without hypertension and diabetes. *PLoS ONE*, **2019**, 14, e0210522	3.7	6
379	Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease. **2019**, 34, 459-469		9
378	[Complications and treatment of mineral and bone disorders in chronic kidney disease]. **2019**, 15, 242-258		3
377	Calcification of breast artery as detected by mammography: association with coronary and aortic calcification. **2019**, 49, 190-197		3
376	Strategies for Phosphate Control in Patients With CKD. *Kidney International Reports*, **2019**, 4, 1043-1056	4.1	48
375	Cardiovascular and renal outcomes following percutaneous coronary intervention in a population with renal disease: a case-control study. **2019**, 112, 669-674		2
374	Diabetes Mellitus Modifies the Associations of Serum Magnesium Concentration With Arterial Calcification and Stiffness in Incident Hemodialysis Patients. *Kidney International Reports*, **2019**, 4, 806-813	4.1	4
373	Vascular calcification-any place left for nicotinamide?. *Nephrology Dialysis Transplantation*, **2020**, 35, 18-22	4.3	1
372	Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. **2019**, 11,		7
371	Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production. **2019**, 20,		6

370	Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. **2019**, 76, 2077-2091		85
369	Sudden Cardiac Death in Dialysis: Arrhythmic Mechanisms and the Value of Non-invasive Electrophysiology. *Frontiers in Physiology*, **2019**, 10, 144	4.6	9
368	High-Urgency Renal Transplantation for Patients With Vascular Access Failure: A Single-Center Experience. **2019**, 51, 1571-1574		
367	The Key Role of Phosphate on Vascular Calcification. **2019**, 11,		59
366	Spironolactone dose-dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit-1. **2019**, 19, 3622-3632		8
365	Increased Aortic Arch Calcification and Cardiomegaly is Associated with Rapid Renal Progression and Increased Cardiovascular Mortality in Chronic Kidney Disease. **2019**, 9, 5354		9
364	Vitamin K Dependent Proteins in Kidney Disease. **2019**, 20,		17
363	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. **2019**, 73, 806-814		40
362	Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 751-766	12.7	74
361	The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. **2019**, 9, 14		14
360	Factors and Outcome of Renal Osteodystrophy-Associated Initial Fragility Fracture in End-Stage Renal Disease Patients. **2019**, 5, 118-125		5
359	The association of the ankle-brachial index, the toe-brachial index, and their difference, with mortality and limb outcomes in dialysis patients. **2019**, 23, 214-222		3
358	Clinical implications of fetuin-A. **2019**, 89, 79-130		15
357	Chronic Kidney Disease Is Linked to Carotid Nodular Calcification, An Unstable Plaque Not Correlated to Inflammation. **2019**, 10, 71-81		8
356	Serum fetuin-A is associated with the components of MIAC(malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease. **2019**, 49, 327-335		10
355	The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification-Related Processes. **2019**, 20,		93
354	Diagnostic Tests for Vascular Calcification. **2019**, 26, 445-463		13
353	The double edge of anti-CD40 siRNA therapy: It increases renal microcapillar density but favours the generation of an inflammatory milieu in the kidneys of ApoE mice. **2019**, 16, 25		6

352	Pulse pressure correlates with coronary artery calcification and risk for coronary heart disease: a study of elderly individuals in the rural region of Southwest China. **2019**, 30, 297-302		2
351	Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial. *PLoS ONE*, **2019**, 14, e0225824	3.7	9
350	An overview of the mechanisms in vascular calcification during chronic kidney disease. **2019**, 28, 289-296		24
349	Abdominal aortic calcification is superior to other arteries calcification in predicting the mortality in peritoneal dialysis patients - a 8 years cohort study. **2019**, 20, 439		5
348	Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. **2019**, 234, 4825-4839		12
347	Mineral Bone Disorders in Chronic Kidney Disease. **2019**, 145-161.e6		
346	Apabetalone downregulates factors and pathways associated with vascular calcification. **2019**, 280, 75-84		36
345	Cardiovascular Disease in Chronic Kidney Disease. **2019**, 176-193.e9		
344	F-Fluoride Signal Amplification Identifies Microcalcifications Associated With Atherosclerotic Plaque Instability in Positron Emission Tomography/Computed Tomography Images. **2019**, 12, e007835		56
343	Exosomes from mesenchymal stem cells expressing miR-125b inhibit neointimal hyperplasia via myosin IE. **2019**, 23, 1528-1540		23
342	Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification. **2019**, 38, 134-144		10
341	Microcalcification in the arterial wall and its relationship to the ultrasound criteria of maturation of the arteriovenous fistula. **2019**, 20, 46-51		1
340	Investigational Pharmacological Treatments for Vascular Calcification. **2019**, 2, 1800094		20
339	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, 1202-1211	4.3	11
338	Impact of pretransplant mitral annular calcification on the incidence of cardiac events after renal transplantation. *Nephrology Dialysis Transplantation*, **2020**, 35, 526-533	4.3	2
337	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. **2020**, 3, 209-215		21
336	Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. **2020**, 250, 30-41		23
335	The role of sphingosine 1-phosphate metabolism in bone and joint pathologies and ectopic calcification. **2020**, 130, 115087		4

334	Magnesium prevents vascular calcification in Klotho deficiency. **2020**, 97, 487-501		27
333	Vitamin D receptor activation and prevention of arterial aging. **2020**, 409-425		
332	Oxidative stress contributes to vascular calcification in patients with chronic kidney disease. **2020**, 138, 256-268		32
331	Cardiovascular actions of parathyroid hormone/parathyroid hormone-related protein signaling. **2020**, 623-644		
330	Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry. **2020**, 72, 79-87		3
329	Reversal of phosphate-induced ORAI1 expression, store-operated Ca entry and osteogenic signaling by MgCl in human aortic smooth muscle cells. **2020**, 523, 18-24		3
328	Phenotypic features of vascular calcification in chronic kidney disease. *Journal of Internal Medicine*, **2020**, 287, 422-434	10.8	6
327	Role of SGK1 in the Osteogenic Transdifferentiation and Calcification of Vascular Smooth Muscle Cells Promoted by Hyperglycemic Conditions. **2020**, 21,		5
326	Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging. **2020**, 12,		17
325	Regulation of Vascular Calcification by Reactive Oxygen Species. **2020**, 9,		14
324	Carotid Plaque Morphology is Similar in Patients with Reduced and Normal Renal Function. **2020**, 14, 1179546820951793		
323	KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. **2020**, 76, S1-S107		264
322	Intimal and medial calcification in relation to cardiovascular risk factors. *PLoS ONE*, **2020**, 15, e0235228	3.7	14
321	Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease. **2020**, 21, 279		2
320	Calciprotein Particles Cause Endothelial Dysfunction under Flow. **2020**, 21,		6
319	Hyperphosphatemia Drives Procoagulant Microvesicle Generation in the Rat Partial Nephrectomy Model of CKD. **2020**, 9,		4
318	The effects of mutation and modification on the structure and stability of human lysozyme: A molecular link between carbamylation and atherosclerosis. **2020**, 100, 107703		2
317	The use of activated vitamin D and risks of hospitalization for infection and amputation in incident hemodialysis patients in Taiwan: a nationwide population-based cohort study. **2020**, 21, 331		0

316	Progression of Aortic Arch Calcification Is Associated with Overall and Cardiovascular Mortality in Hemodialysis. **2020**, 2020, 6293185		7
315	Biomechanical signal communication in vascular smooth muscle cells. **2020**, 14, 357-376		10
314	Transcriptional Programming in Arteriosclerotic Disease: A Multifaceted Function of the Runx2 (Runt-Related Transcription Factor 2). **2021**, 41, 20-34		13
313	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 2653-2666	12.7	22
312	Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. **2020**, 21,		18
311	Blood Pressure is Associated with Rapid Kidney Function Decline in a Very Elderly Hypertensive Chinese Population. **2020**, 15, 1317-1323		1
310	Vascular Calcification Slows But Does Not Regress After Kidney Transplantation. *Kidney International Reports*, **2020**, 5, 2212-2217	4.1	7
309	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. **2020**, 9,		8
308	Coronary Artery Disease in patients with End-Stage Kidney Disease; Current perspective and gaps of knowledge. **2020**, 33, 187-197		2
307	Quantified Vascular Calcification at the Dialysis Access Site: Correlations with the Coronary Artery Calcium Score and Survival Analysis of Access and Cardiovascular Outcomes. **2020**, 9,		1
306	Current Therapy in CKD Patients Can Affect Vitamin K Status. **2020**, 12,		6
305	Implications of Kidney Disease in the Cardiac Patient. **2020**, 9, 265-278		1
304	Balloon Angioplasty of Infrapopliteal Arteries: A Systematic Review and Proposed Algorithm for Optimal Endovascular Therapy. **2020**, 27, 547-564		14
303	Stimulation of ORAI1 expression, store-operated Ca entry, and osteogenic signaling by high glucose exposure of human aortic smooth muscle cells. **2020**, 472, 1093-1102		1
302	Effect of high-dose vitamin D supplementation on peripheral arterial calcification: secondary analysis of a randomized controlled trial. **2020**, 31, 2141-2150		1
301	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. **2020**, 76, 109-120		4
300	The relationship between atherosclerosis and bone mineral density in patients with type 2 diabetes depends on vascular calcifications and sex. **2020**, 31, 1135-1143		4
299	Different Ultrasound Scoring Methods for Assessing Medial Arterial Calcification: Association with Diabetic Complications. **2020**, 46, 1365-1372		3

298	High dose haemodialysis and haemodiafiltration parameters and the relationship with advanced vascular calcification. **2020**, 21, 86		0
297	Effects of repetitive diet-induced fluctuations in plasma phosphorus on vascular calcification and inflammation in rats with early-stage chronic kidney disease. **2020**, 66, 139-145		4
296	Arterial Stiffness: A Focus on Vascular Calcification and Its Link to Bone Mineralization. **2020**, 40, 1078-1093		40
295	The Novel -Dihydroperoxide 12AC3O Suppresses High Phosphate-Induced Calcification via Antioxidant Effects in p53LMAco1 Smooth Muscle Cells. **2020**, 21,		1
294	The biology of vascular calcification. **2020**, 354, 261-353		6
293	Predictors of Renal Failure in Patients Treated With the Total Artificial Heart. **2020**, 26, 588-593		0
292	Beta-Glycerophosphate-Induced ORAI1 Expression and Store Operated Ca Entry in Megakaryocytes. **2020**, 10, 1728		4
291	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. **2020**, 9,		3
290	Arterial Medial Calcification through Enhanced small Extracellular Vesicle Release in Smooth Muscle-Specific Asah1 Gene Knockout Mice. **2020**, 10, 1645		11
289	The predictive value of serum galectin 3 for abdominal aortic calcification in maintenance hemodialysis patients: A prospective cohort study. **2020**, 24, 212-220		2
288	The pathogenesis of CKD complications; Attack of dysregulated iron and phosphate metabolism. **2020**, 157, 55-62		3
287	Fine particulate matter and cause-specific mortality in the Hong Kong elder patients with chronic kidney disease. **2020**, 247, 125913		12
286	Choosing between anatomy and function is not always evident for the heart of end-stage renal disease patients. How low can we go?. **2020**, 1		0
285	Incidence of Ischaemic Heart Disease in Men and Women With End-Stage Kidney Disease: A Cohort Study. **2020**, 29, 1517-1526		2
284	A five-year longitudinal study of the relation between end-stage kidney disease as the outcomes. **2020**, 21, 132		
283	Effect of Low-Sodium versus Conventional Sodium Dialysate on Left Ventricular Mass in Home and Self-Care Satellite Facility Hemodialysis Patients: A Randomized Clinical Trial. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 1078-1091	12.7	13
282	Uremic Vascular Calcification Is Correlated With Oxidative Elastic Lamina Injury, Contractile Smooth Muscle Cell Loss, Osteogenesis, and Apoptosis: The Human Pathobiological Evidence. *Frontiers in Medicine*, **2020**, 7, 78	4.9	9
281	Evaluation of aortic calcification using a three-dimensional volume-rendering method in patients with end-stage kidney disease. **2021**, 39, 439-445		1

280	Association between serum lipids, polyunsaturated fatty acids, and prognosis in maintenance hemodialysis patients. **2020**,		1
279	Vascular calcification by conventional X-ray and mortality in a cohort of predominantly African descent hemodialysis patients. **2021**, 44, 318-324		0
278	A Novel Scoring System for Small Artery Disease and Medial Arterial Calcification Is Strongly Associated With Major Adverse Limb Events in Patients With Chronic Limb-Threatening Ischemia. **2021**, 28, 194-207		5
277	Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. *Calcified Tissue International*, **2021**, 108, 410-422	3.9	19
276	Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions. **2021**, 162, 389-415		1
275	Association of hyperphosphatemia with an increased risk of sudden death in patients on hemodialysis: Ten-year outcomes of the Q-Cohort Study. **2021**, 316, 25-31		3
274	Association between indocyanine green fluorescence blood flow speed in the gastric conduit wall and superior mesenteric artery calcification: predictive significance for anastomotic leakage after esophagectomy. **2021**, 18, 248-257		6
273	Association of time-updated plasma calcium and phosphate with graft and patient outcomes after kidney transplantation. **2021**, 21, 2437-2447		1
272	Promoting cardiovascular health post-transplant through early diagnosis and adequate management of hypertension and dyslipidemia. **2021**, 25, e13811		3
271	Vasopressin-stimulated ORAI1 expression and store-operated Ca entry in aortic smooth muscle cells. **2021**, 99, 373-382		0
270	Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. **2021**, 99, 335-348		15
269	Role of crosstalk between endothelial cells and smooth muscle cells in vascular calcification in chronic kidney disease. **2021**, 54, e12980		8
268	Vascular calcification of chronic kidney disease: A brief review. **2021**, 33, 34-41		1
267	Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification. *Calcified Tissue International*, **2021**, 108, 798-807	3.9	0
266	ESKD Complications: CKD-MBD. **2021**, 211-231		
265	Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 723-735	12.7	14
264	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. *PLoS ONE*, **2021**, 16, e0247623	3.7	3
263	Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial). **2021**, 11,		1

262	Approach to stable angina in patients with advanced chronic kidney disease. **2021**, 30, 339-345		1
261	Effect of MgCl and GdCl on ORAI1 Expression and Store-Operated Ca Entry in Megakaryocytes. **2021**, 22,		0
260	Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients. **2021**, 77, 346-354		4
259	The Thermodynamics of Medial Vascular Calcification. **2021**, 9, 633465		4
258	The Pharmacological Effect and Mechanism of Lanthanum Hydroxide on Vascular Calcification Caused by Chronic Renal Failure Hyperphosphatemia. **2021**, 9, 639127		1
257	Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options. **2021**, 1		5
256	High ankle-brachial index predicts cardiovascular events and mortality in hemodialysis patients with severe secondary hyperparathyroidism. **2021**,		
255	Lysosome Function in Cardiovascular Diseases. **2021**, 55, 277-300		0
254	The Importance of Phosphate Control in Chronic Kidney Disease. **2021**, 13,		5
253	Different Lower Extremity Arterial Calcification Patterns in Patients with Chronic Limb-Threatening Ischemia Compared with Asymptomatic Controls. **2021**, 11,		0
252	The Relationship between Advanced Oxidation Protein Products, Vascular Calcifications and Arterial Stiffness in Predialysis Chronic Kidney Disease Patients. **2021**, 57,		1
251	Association between serum magnesium levels and abdominal aorta calcification in patients with pre-dialysis chronic kidney disease stage 5. *PLoS ONE*, **2021**, 16, e0253592	3.7	2
250	Recent developments, current challenges and future perspectives on cellulosic hemodialysis membranes for highly efficient clearance of uremic toxins. **2021**, 27, 102183		11
249	Association of Serum Sclerostin Level, Coronary Artery Calcification, and Patient Outcomes in Maintenance Dialysis Patients. **2021**, 1-10		1
248	Evaluating the Independent Impact of Renal Function Decline on Coronary Artery Calcification in Patients Undergone Cardiac CT Scan. **2021**, 13,		
247	Monckeberg's Medial Sclerosis as a Cause for Headache and Facial Pain. **2021**, 25, 50		2
246	Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. **2021**, 99, 1382-1391		2
245	Heat Shock Proteins: Connectors between Heart and Kidney. **2021**, 10,		4

244	The association between atrial fibrillation and in-hospital outcomes in chronic kidney disease patients with acute coronary syndrome: findings from the improving care for cardiovascular disease in China-acute coronary syndrome (CCC-ACS) project. *BMC Cardiovascular Disorders*, **2021**, 21, 345	2.3	
243	Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients. **2021**, 18,		2
242	Vascular Calcification Mechanisms: Updates and Renewed Insight into Signaling Pathways Involved in High Phosphate-Mediated Vascular Smooth Muscle Cell Calcification. *Biomedicines*, **2021**, 9,	4.8	6
241	The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism. **2021**, 13,		5
240	Relationship between intact parathyroid hormone and all-cause death, cardiovascular events, and ectopic calcification in patients with diabetic kidney disease: A retrospective study. **2021**, 177, 108926		
239	Analysis of the Prevalence and Severity of Dysregulated Bone Mineral Homeostasis in Nondialyzed Chronic Kidney Disease Patients.		
238	Diagnostic performance of computed tomography digital subtraction angiography of the lower extremities during haemodialysis in patients with suspected peripheral artery disease. **2021**, 27, 888-896		1
237	Calcified facial and maxillary arteries: Incidental radiographic findings indicative of M□ckeberg arteriosclerosis. **2021**, 152, 943-946		1
236	Prognostic Implication of Longitudinal Changes in Cardiothoracic Ratio and Aortic Arch Calcification in Hemodialysis Patients. **2021**, 11,		1
235	Serum soluble (pro)renin receptor level as a prognostic factor in patients undergoing maintenance hemodialysis. **2021**, 11, 17402		1
234	Comparison of two-year clinical outcomes according to glycemic status and renal function in patients with acute myocardial infarction following implantation of new-generation drug-eluting stents. **2021**, 35, 108019		0
233	Phosphate Balance and CKD-Mineral Bone Disease. *Kidney International Reports*, **2021**, 6, 2049-2058	4.1	2
232	Efficacy of Statin Treatment According to Baseline Renal Function in Korean Patients with Acute Myocardial Infarction Not Requiring Dialysis Undergoing Newer-Generation Drug-Eluting Stent Implantation. **2021**, 10,		0
231	Low Muscle Mass in Patients Receiving Hemodialysis: Correlations with Vascular Calcification and Vascular Access Failure. **2021**, 10,		1
230	Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States. **2021**, 264, 444-453		0
229	Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. **2021**, 14, 301-311		
228	Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease. **2021**, 11,		2
227	Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population. **2021**, 10, 76-87		1

226	Vascular Calcification and Cardiovascular Risk in Chronic Kidney Disease: A Problem That Is Here to Stay.	
225	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. **2021**, 19, 2984-2996	0
224	Disparate Information Provided by Pulse Wave Velocity versus Other Measures of Aortic Compliance in End-Stage Renal Disease. **2021**, 1-11	0
223	Increased β-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling. **2021**, 473, 1899-1910	2
222	Calcification and Aortic Syndromes. **2022**, 65-93	
221	Medial Arterial Calcification: JACC State-of-the-Art Review. **2021**, 78, 1145-1165	12
220	The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients. **2021**, 52, 763-770	
219	Cardiovascular Calcification in Systemic Diseases. **2022**, 259-287	
218	A feline-focused review of chronic kidney disease-mineral and bone disorders - Part 2: Pathophysiology of calcium disorder and extraosseous calcification. **2021**, 275, 105718	0
217	Association of Arterial Stiffness With Chronic Kidney Disease Progression and Mortality. **2021**, 30, 1694-1701	0
216	Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. **2021**, 52, 304-317	
215	Breast arterial calcifications as an indicator of atherosclerotic cardiovascular disease: comparative analysis of coronary computed tomography scoring systems and carotid intima-media thickness.. **2022**, 12, 457-469	0
214	SLC37A2, a phosphorus-related molecule, increases in smooth muscle cells in the calcified aorta. **2021**, 68, 23-31	0
213	Parenchymal biopsy in the management of patients with renal cancer. **2021**, 39, 2961-2968	6
212	Calcification of lower extremity arteries is related to the presence of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a cross-sectional observational study. **2021**, 32, 1185-1193	4
211	Vascular Calcification in Chronic Kidney Disease. **2009**, 697-711	2
210	Long-Term Outcome of Chronic Dialysis in Children. **2012**, 645-660	2
209	Vascular and Valvular Calcification in Chronic Kidney Disease: Pathogenesis and Clinical Outcomes. **2017**, 11-20	1

208	Disorders of Bone Mineral Metabolism in Chronic Kidney Disease. **2016**, 1533-1566		1
207	Cardiovascular Aspects of Kidney Disease. **2012**, 2059-2080		5
206	The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. **2020**, 508, 221-227		9
205	Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. **2020**, 11, 721		23
204	Magnesium to prevent kidney disease-associated vascular calcification: crystal clear?. *Nephrology Dialysis Transplantation*, **2020**,	4.3	7
203	Emerging roles of fibroblasts in cardiovascular calcification. **2021**, 25, 1808-1816		5
202	Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. *Circulation*, **2005**, 112, I270-5	16.7	94
201	Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. **2005**, 115, 1210-20		335
200	Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. **2013**, 123, 812-22		102
199	Association of infrapopliteal medial arterial calcification with lower-limb amputations in high-risk patients: A systematic review and meta-analysis. **2021**, 26, 164-173		3
198	Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy. **2005**, 99, 89-94		21
197	In-Hospital outcomes in acute coronary syndrome patients with concomitant severe chronic kidney disease undergoing percutaneous coronary intervention. **2019**, 35, 291-297		5
196	Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. **2014**, 6, 72		10
195	Characterization of granulations of calcium and apatite in serum as pleomorphic mineralo-protein complexes and as precursors of putative nanobacteria. *PLoS ONE*, **2009**, 4, e5421	3.7	69
194	Progression of aortic arch calcification over 1 year is an independent predictor of mortality in incident peritoneal dialysis patients. *PLoS ONE*, **2012**, 7, e48793	3.7	26
193	Functional MRI in peripheral arterial disease: arterial peak flow versus ankle-brachial index. *PLoS ONE*, **2014**, 9, e88471	3.7	5
192	Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization. *PLoS ONE*, **2014**, 9, e101709	3.7	8
191	Axl tyrosine kinase protects against tubulo-interstitial apoptosis and progression of renal failure in a murine model of chronic kidney disease and hyperphosphataemia. *PLoS ONE*, **2014**, 9, e102096	3.7	14

190	N-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse models. *PLoS ONE*, **2015**, 10, e0122650	3.7	15
189	Arterial Expression of the Calcium-Sensing Receptor Is Maintained by Physiological Pulsation and Protects against Calcification. *PLoS ONE*, **2015**, 10, e0138833	3.7	17
188	Serum Magnesium and Sudden Death in European Hemodialysis Patients. *PLoS ONE*, **2015**, 10, e0143104	3.7	55
187	Role of UBIAD1 in Intracellular Cholesterol Metabolism and Vascular Cell Calcification. *PLoS ONE*, **2016**, 11, e0149639	3.7	9
186	Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia. *PLoS ONE*, **2016**, 11, e0158964	3.7	15
185	Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells. *PLoS ONE*, **2017**, 12, e0180393	3.7	13
184	THE ENDOCRINE FUNCTION OF THE BONE TISSUE. **2015**, 18, 28-37		3
183	Arterial stiffness may predict renal and cardiovascular prognosis in autosomal-dominant polycystic kidney disease. **2018**, 105, 145-156		1
182	[Osteoprotegerin: regulator, protector and marker]. **2008**, 149, 1971-80		4
181	The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. **2019**, 11, 4274-4299		32
180	Central and peripheral blood pressures and arterial stiffness increase in hypoparathyroidism. **2020**, 64, 374-382		3
179	Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary. **2018**, 14, 192-199		11
178	Parathyroidectomy in the Management of Secondary Hyperparathyroidism. **2018**, 13, 952-961		47
177	High Fetuin-A Level as a Protective Factor to Abdominal Aortic Calcification in Indonesian Regular Hemodialysis Patients. **2019**, 7, 721-725		6
176	Pre-existing arterial pathologic changes affecting arteriovenous fistula patency and cardiovascular mortality in hemodialysis patients. **2017**, 32, 790-797		13
175	Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients. **2011**, 21, 90-4		11
174	Evaluation of the relationship between blood cell parameters and vascular calcification in dialysis-dependent end-stage renal disease patients. **2020**, 31, 136-143		3
173	Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?. **2014**, 6, 216-26		15

172	Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. **2012**, 78, 1-9	20
171	Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease. **2012**, 1, 25-34	17
170	Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication. **2012**, 1, 43-53	55
169	Lowering vascular calcification burden in chronic kidney disease: Is it possible?. **2013**, 2, 49-55	4
168	Pre-treatment considerations in childhood hypertension due to chronic kidney disease. **2015**, 4, 500-10	5
167	Vascular calcification: When should we interfere in chronic kidney disease patients and how?. **2016**, 5, 398-417	11
166	Role of different imaging modalities of vascular calcification in predicting outcomes in chronic kidney disease. **2017**, 6, 100-110	17
165	Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. **2017**, 6, 212302	2
164	Monckeberg Medial Calcific Sclerosis of the Temporal Artery Masquerading as Giant Cell Arteritis: Case Reports and Literature Review. **2020**, 12, e9210	1
163	Bacterial metabolites and cardiovascular risk in children with chronic kidney disease. **2021**, 8, 17	0
162	Higher Blood Lead Level Is Associated With Increased Likelihood of Abdominal Aortic Calcification. **2021**, 8, 747498	0
161	Co-relation Between Calcium-Phosphorus Product and Hypertension in End-Stage Renal Disease Patients. **2021**, 13, e18885	0
160	Chronic Kidney Disease. **2006**, 463-500	
159	5. ????????????????. **2007**, 40, 138-139	
158	Cardiovascular Complications after Renal Transplantation. **2008**, 469-491	
157	Management of Calcium and Bone Disease in Renal Patients. **2008**, 2671-2679	
156	Intensive versus standard haemodialysis water treatment for preventing low grade mineral intoxication in chronic haemodialysed patients.	
155	Different Ankle Brachial Index Levels in Asymptomatic Hemodialysis Patients. **2008**, 1, 44-49	

154	Anaemia as a Risk Factor for Cardiovascular Disease in Patients with Chronic Kidney Disease. **2008**, 8, 707-714	
153	Inflamaci□ y riesgo cardiovascular en di□sis peritoneal. **2009**, 361-377	
152	Changes of serum fibroblast growth factor 23 in patients with end stage renal disease and its clinical significance. **2009**, 28, 1184-1187	
151	Disturbed Calcium-Phosphorus Metabolism/Arterial Calcifications: Consequences on Cardiovascular Function and Clinical Outcome. **2010**, 269-277	1
150	Natural History and Impact of Interventions on Coronary Calcium. **2010**, 59-68	
149	Chronic Kidney Disease-Mineral Bone Disorder. **2011**, 2021-2058	1
148	Vitamin D: Cardiovascular Effects and Vascular Calcification. **2011**, 1403-1426	0
147	Controle da hiperfosfatemia na DRC. **2011**, 33, 261-267	
146	Dietary Paradoxes to Optimize Cardiovascular Risk Management in Chronic Kidney Disease. **2012**, 213-237	
145	Vaskul□e Untersuchungsmethoden. **2012**, 185-213	
144	Modifications of Coronay Artery Calcifications (CAC) and Correlations with C Reactive Protein (CRP) Levels in Renal Recipients after the First Year of Transplantation. **2013**, 03, 1-5	
143	(3) ?????. **2013**, 46, 352-355	
142	Endothelial Dysfunction in Patients with Chronic Kidney Disease. **2013**, 356-372	
141	Intensive versus standard haemodialysis water treatment for preventing low grade aluminium intoxication in chronic haemodialysed patients.	
140	Clinical Implication of Vascular Calcification in Patients Undergoing Hemodialysis: The End or the Beginning of Disease. **2014**, 87, 39	
139	Vascular Calcification. **2014**, 1-18	
138	Large Artery Remodeling and Chronic Kidney Disease. **2014**, 339-350	
137	Vascular calcification is not associated with increased ambulatory central aortic systolic pressure in prevalent dialysis patients. **2014**, 25, 4-8	

136 Vascular Access Calcification and Arteriovenous Fistula Maturation. **2014**, 7, 22-25

135 Sudden Cardiac Death and Arrhythmia in CKD. **2015**, 19-27

134 Chronic Kidney Disease and Renovascular Interactions. **2015**, 299-312

133 [Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease]. **2015**, 87, 54-61 1

132 Vascular Calcification. **2015**, 327-341

131 Evaluation of Calcified Carotid Artery Atheromas Detected By Panoramic Radiograph among Patients with Type II Diabetes Mellitus. 048-052

130 Natural History and Impact of Interventions on CAC. **2016**, 121-132

129 The Association Between MGP Gene Polymorphisms and Coronary Artery Disease. **2016**, 7,

128 Nicht-bildgebende apparative Diagnostik von Gef□rkrankungen. **2017**, 1-14

127 Nicht-apparative Diagnostik von Gef□rkrankungen. **2017**, 1-4

126 MR-Angiographie in der Gef□□edizin. **2017**, 1-6

125 Assessment of Arterial Stiffening and Vascular Calcifications in End-Stage Renal Disease Patients. **2017**, 07, 131-143

124 Factors associated with early mortality in haemodialysis patients undergoing coronary artery bypass surgery. **2017**, 28, 108-111 1

123 Removal Estimation of Uremic CVD Marker Phosphate in Dialysis Using Spectrophoto-and Fluorimetrical Signals. **2018**, 358-361 1

122 Clinical and Preclinical Evidence of the Skeletal and Vascular Adverse Health Effects of High Dietary Phosphorus. **2017**, 31-44

121 Clinical Practices and Therapeutic Management of Mineral and Bone Disorders in Chronic Kidney Disease 4, 5 and 5D: The OCEANOS Study in Iran. **2017**, 10, 1

120 CKD-MBD?? ; ????????. **2018**, 51, 631-640

119 Associations of vascular calcification, calcium phosphate disturbances, FGF 23 and Matrix Gla protein with mortality of hemodialysis patients: one center cohort study. **2018**, 26, 451-460 2

118	Does Vitamin K Intake Influence High Phosphate Induced Vascular Pseudo-ossification: An Underappreciated Therapeutic Prospect in General Population?. **2019**, 20, 421-430		
117	Markers of Atherosclerosis in Hypertensive Patients with Less Advanced Chronic Kidney Disease. **2019**, 65, 91-96		
116	Chronic Kidney Disease-Mineral and Bone Disorder, Vitamin D Deficiency, and Secondary Hyperparathyroidism. **2020**, 141-151		
115	[Mönkeberg's sclerosis: role of calcification in arterial lesions in patients with diabetes mellitus]. **2020**, 26, 17-22		0
114	Circulating Fibroblast Growth Factor-23 is Associated with Cardiovascular Prognosis and Graft Function in Renal Transplant Recipients. **2020**, 12, e7140		1
113	Loss of PKCδ increases arterial medial calcification in a uremic mouse model of chronic kidney disease.		
112	Association between renal function impairment and multivessel involvement in patients with acute ST-elevation myocardial infarction. **2020**, 12, 10863-10872		0
111	[Vitamin D and laboratory indicators of cardiovascular risk in the elderly.]. **2020**, 65, 11-15		
110	The Role of Elastin Degradation in Vascular Calcification: Possibilities to Repair Elastin and Reverse Calcification. **2020**, 441-480		1
109	Progression of coronary artery calcification in conventional hemodialysis, nocturnal hemodialysis, and kidney transplantation. *PLoS ONE*, **2020**, 15, e0244639	3.7	0
108	Magnesium, the Novel Member of the CKD-MBD Family. **2020**, 19, 181-185		
107	Vascular Calcification in CKD. **2020**, 19, 226-241		
106	Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder. **2022**, 353-381		
105	Nicht-apparative Diagnostik von Gefäßerkrankungen. **2020**, 147-150		
104	MR-Angiographie in der Gefäßmedizin. **2020**, 179-184		
103	Nicht-bildgebende apparative Diagnostik von Gefäßerkrankungen. **2020**, 151-164		
102	The Role of Calcification in Peripheral Artery Disease. **2020**, 167-181		
101	Effects of dietary fiber on vascular calcification by repetitive diet-induced fluctuations in plasma phosphorus in early-stage chronic kidney disease rats. **2020**, 67, 283-289		1

100	Epidermal Growth Factor Receptor Inhibition Prevents Caveolin-1-dependent Calcifying Extracellular Vesicle Biogenesis.	0
99	Vascular calcification has a role in acute non-renal phosphate clearance.	1
98	Role Of Vitamin K Therapy In Prevention Of Vascular Calcification In Chronic Kidney Disease. **2020**, 2,	1
97	Multiple extremity necrosis in fatal calciphylaxis: Case report. **2021**, 43, 274-278	
96	Natural History and Impact of Interventions on Coronary Calcium. **2006**, 97-106	
95	Disorders of Phosphorous Homeostasis in CKD. **2006**, 13-28	
94	Therapy of chronic renal insufficiency: from renal physiology to cardiovascular outcomes. **2005**, 2, 425-437	
93	Sevelamer hydrochloride: a calcium- and metal-free phosphate binder. **2005**, 2, 823-834	
92	Prevalence and Progression of Cardiovascular Calcification in the General Population and Patients with Chronic Kidney Disease. **2021**, 7-18	
91	Noninvasive measurements of arterial stiffness: repeatability and interrelationships with endothelial function and arterial morphology measures. **2007**, 3, 343-9	30
90	Osteoporosis and cardiovascular disease: lessons from chronic kidney disease. **2008**, 5, 35-9	3
89	Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value. **2005**, 1, 43-63	2
88	Klotho protein lowered in elderly hypertension. **2014**, 7, 2347-50	11
87	Association of CaPO4 product with levels of serum C-reactive protein in regular hemodialysis patients. **2012**, 1, 55-9	1
86	The diagnostic accuracy of stress myocardial perfusion scintigraphy in patients with end-stage renal disease. **2021**, 11, 246-252	
85	Sex Differences in Fecal Microbiota Correlation With Physiological and Biochemical Indices Associated With End-Stage Renal Disease Caused by Immunoglobulin a Nephropathy or Diabetes.. **2021**, 12, 752393	1
84	Zinc Ameliorates the Osteogenic Effects of High Glucose in Vascular Smooth Muscle Cells. **2021**, 10,	4
83	The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. **2021**,	1

82	Outcome of early versus delayed invasive strategy in patients with non-ST-segment elevation myocardial infarction and chronic kidney disease not on dialysis.. **2021**,		0
81	Control of hyperphosphatemia and maintenance of calcemia in CKD.. **2021**, 43, 632-638		
80	Association between bone mineral metabolism and vascular calcification in end-stage renal disease.. **2022**, 23, 12		2
79	Unspliced XBP1 Counteracts β-catenin to Inhibit Vascular Calcification. **2021**,		2
78	Cardiometabolic Syndrome and Vascular Calcification. 2,		
77	Epidemiology of cardiovascular death in kidney failure: an Australian and New Zealand cohort study using data linkage.. *Nephrology*, **2022**,	2.2	1
76	Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease.. *Nephrology Dialysis Transplantation*, **2022**,	4.3	3
75	The impact of chronic kidney disease on coronary revascularization. **2022**, 525-541		
74	Scoring of medial arterial calcification predicts cardiovascular events and mortality after kidney transplantation.. *Journal of Internal Medicine*, **2022**,	10.8	2
73	Protective Roles of Xenotropic and Polytropic Retrovirus Receptor 1 (XPR1) in Uremic Vascular Calcification.. *Calcified Tissue International*, **2022**, 1	3.9	0
72	Past, Present, and Future of Phosphate Management.. *Kidney International Reports*, **2022**, 7, 688-698	4.1	3
71	Cardiorenal Function and Survival in In-Hospital Cardiac Arrest: A Nationwide Study of 22,819 Cases.. *Resuscitation*, **2022**,	4	
70	Mid-Term Results of Surgical Aortic Valve Replacement with Bioprostheses in Hemodialysis Patients. *SSRN Electronic Journal*,	1	
69	Acute myocardial infarction and acute heart failure among renal transplant recipients: a national readmissions database study.. *Journal of Nephrology*, **2022**,	4.8	0
68	NRF2-suppressed vascular calcification by regulating the antioxidant pathway in chronic kidney disease.. *FASEB Journal*, **2022**, 36, e22098	0.9	2
67	Cholesterol in vascular and valvular calcification. *Circulation*, **2001**, 104, 1881-3	16.7	16
66	Phosphate Is a Cardiovascular Toxin.. *Advances in Experimental Medicine and Biology*, **2022**, 1362, 107-134	3.6	0
65	Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.. *Advances in Experimental Medicine and Biology*, **2022**, 1362, 47-54	3.6	1

64	Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification.. *Clinical and Translational Medicine*, **2022**, 12, e682	5.7	1
63	Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease.. *PLoS ONE*, **2022**, 17, e0265050	3.7	0
62	Identification of potential biomarkers of vascular calcification using bioinformatics analysis and validation .. *PeerJ*, **2022**, 10, e13138	3.1	1
61	Requirement of Na+/H+ exchanger NHE1 for vasopressin-induced osteogenic signaling and calcification in human aortic smooth muscle cells.. *Kidney and Blood Pressure Research*, **2022**,	3.1	0
60	Vascular Stiffness in Aging and Disease.. *Frontiers in Physiology*, **2021**, 12, 762437	4.6	6
59	Non-classical Vitamin D Actions for Renal Protection.. *Frontiers in Medicine*, **2021**, 8, 790513	4.9	1
58	Two-year outcomes between ST-elevation and non-ST-elevation myocardial infarction in patients with chronic kidney disease undergoing newer-generation drug-eluting stent implantation.. *Catheterization and Cardiovascular Interventions*, **2021**,	2.7	0
57	Mechanisms of calcification in the aortic wall and aortic valve. **2022**, 327-340		
56	Association of serum creatinine with aortic arch calcification in middle-aged and elderly adults: an observational cross-sectional study from China.. *BMC Cardiovascular Disorders*, **2022**, 22, 167	2.3	1
55	Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patients.. *IJC Heart and Vasculature*, **2022**, 40, 101030	2.4	
54	Image_1.tiff. **2018**,		
53	Image_2.tiff. **2018**,		
52	A Reproducible Mouse Model of Moderate CKD With Early Manifestations of Osteoblastic Transition of Cardiovascular System.. *Frontiers in Physiology*, **2022**, 13, 897179	4.6	
51	Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomisation study.		
50	Lanthanum hydroxide inhibits vascular calcification by regulating the HIF-1 pathway.. *Cell Biology International*, **2022**,	4.5	1
49	The Relationship Between Pulse Pressure and Hypervolemia in Hemodialysis Patients. *Medical Journal of Western Black Sea*, **2021**, 5, 380-385	3.5	
48	Kidney dysfunction is a significant risk factor for 30-day postoperative complications following shoulder arthroplasty. *Seminars in Arthroplasty*, **2022**,	0.4	
47	The ameliorative effect of berberine on vascular calcification by inhibiting endoplasmic reticulum stress.. *Journal of Cardiovascular Pharmacology*, **2022**,	3.1	

46	Impaired Mineral Ion Metabolism in a Mouse Model of Targeted Calcium-Sensing Receptor (CaSR) Deletion from Vascular Smooth Muscle Cells.. *Journal of the American Society of Nephrology: JASN*, **2022**,	12.7	0
45	Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients. *Frontiers in Medicine*, 9,	4.9	
44	Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation. *Biomedicines*, **2022**, 10, 1496	4.8	
43	Lessons learnt from progressive vascular calcification in a renal transplant recipient. *Indian Journal of Transplantation*, **2022**, 16, 230	0.2	
42	Catalysis-independent ENPP1 protein signaling regulates mammalian bone mass. *Journal of Bone and Mineral Research*,	6.3	1
41	The crosstalk between endothelial cells and vascular smooth muscle cells aggravates high phosphorus-induced arterial calcification. **2022**, 13,		0
40	Relationship between serum parathyroid hormone levels and abdominal aortic calcification in patients starting hemodialysis who have never taken calcium tablets, calcitriol, or vitamin D analogs. **2022**, 44, 1409-1416		
39	Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan.		1
38	Impact of Parathyroid Hormone Level on Intracoronary Calcification and Short- and Long-Term Outcomes in Dialysis Patients Undergoing Percutaneous Coronary Intervention. **2022**,		0
37	A comparative study of coronary artery calcification in dialysis patients between diabetic nephropathy and non-diabetic nephropathy groups. **2022**, 55, 485-491		0
36	Pediatric Mineral and Bone Disorder of Chronic Kidney Disease and Cardiovascular Disease. **2022**, 29, 275-282		0
35	Vascular Aging and COVID-19. 000331972211210		1
34	Coronary and extra-coronary artery calcium scores as predictors of cardiovascular events and mortality in chronic kidney disease stages 1–5: a prospective cohort study.		0
33	Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease. **2022**, 23,		2
32	Mönckeberg's Medial Arteriosclerosis in the Oral and Maxillofacial Region: A Pilot Study.		0
31	Vascular calcification maladaptively participates in acute phosphate homeostasis.		1
30	Long-term outcomes of intermediate coronary stenosis in patients undergoing hemodialysis after deferred revascularization based on fractional flow reserve.		0
29	Comprehensive assessment of cardiovascular complications in a patient with type 1 diabetes mellitus, chronic kidney disease and diabetic neuroosteoarthropathy. **2022**, 50, 205-215		0

28	The effects for inflammatory responses by CPP with different colloidal properties in hemodialysis patients. **2022**, 12,	0
27	The Role of Ultrasound in Accessing the Distal Radial Artery at the Anatomical Snuffbox for Cardiovascular Interventions. **2023**, 13, 25	1
26	Should vitamin K antagonists ever be used in ESRD?.	0
25	Doppler ultrasound assessment of calcified radial arteries prior to radio-cephalic arterio-venous fistula placement: an observational study. 112972982211435	0
24	Targeting a Silent Disease: Vascular Calcification in Chronic Kidney Disease. **2022**, 23, 16114	0
23	Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. CJN.05080422	0
22	High Prevalence of Lower Extremity Medial Arterial Calcification in HIV-infected Patients with and without Chronic Renal Disease: A Vascular Ultrasound Cross-sectional Study. **2022**, 16,	0
21	Abdominal aortic calcification score can predict all-cause and cardiovascular mortality in maintenance hemodialysis patients. **2023**, 45,	0
20	The Age□Stiffness Relationships of Elastic and Muscular Arteries in a Control Population and in End-Stage Renal Disease Patients. **2023**, 3, 36-45	0
19	Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone histomorphometry. **2023**,	0
18	Understanding Atherosclerosis Pathophysiology: Can Additive Manufacturing Be Helpful?. **2023**, 15, 480	0
17	High-Phosphate-Stimulated Macrophage-Derived Exosomes Promote Vascular Calcification via let-7b-5p/TGFBR1 Axis in Chronic Kidney Disease. **2023**, 12, 161	0
16	Medial artery calcification in peripheral artery disease. 10,	0
15	Left sided valvular heart disease in dialysis recipients: a single centre observational study.	0
14	Disorders of Bone Mineral Metabolism in Chronic Kidney Disease. **2023**, 1631-1668	0
13	Inflammatory, Metabolic, and Coagulation Effects on Medial Arterial Calcification in Patients with Peripheral Arterial Disease. **2023**, 24, 3132	1
12	Specialty Balloons for Vessel Preparation During Infrainguinal Endovascular Revascularization Procedures: A Review of Literature. 153857442311560	0
11	Hydrogen sulfide as an anti-calcification stratagem in human aortic valve: Altered biogenesis and mitochondrial metabolism of H2S lead to H2S deficiency in calcific aortic valve disease. **2023**, 60, 102629	1

10	The context-dependent role of transforming growth factor-β/miR-378a-3p/connective tissue growth factor in vascular calcification: a translational study. **2023**, 15, 830-845	0
9	Epidermal growth factor receptor inhibition prevents vascular calcifying extracellular vesicle biogenesis. **2023**, 324, H553-H570	0
8	Effect of magnesium on vascular calcification in chronic kidney disease patients: a systematic review and meta-analysis. **2023**, 45,	0
7	Serum sclerostin in vascular calcification in CKD: a meta-analysis. **2023**, 45,	0
6	Association between Serum Magnesium and Fractures: A Systematic Review and Meta-Analysis of Observational Studies. **2023**, 15, 1304	0
5	Associations of Breast Arterial Calcifications with Cardiovascular Disease.	0
4	Drug-Coated Balloon and Drug-Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. **2023**, 12,	0
3	Mendelian randomization and the association of fibroblast growth factor-23 with heart failure with preserved ejection fraction. Publish Ahead of Print,	0
2	Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group. **2023**,	0
1	Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. **2023**, 132, 993-1012	0